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ABSTRACT 
Levosimendan is a new drug for the treatment of heart failure. Its mechanism of action includes 
calcium sensitization of contractile proteins and the opening of ATP-sensitive potassium 
channels. The combination of positive inotropy with possible anti-ischaemic effects via 
potassium channel opening may offer benefits in comparison with currently available 
intravenous inotropes, which are contraindicated in patients with ongoing myocardial 
ischaemia. The active levosimendan metabolite OR-1896, with properties similar to those of the 
parent drug, significantly prolongs the duration of the haemodynamic effects of levosimendan. 
The main aims of the present study were to investigate: 1) the clinical effects and safety of 
intravenous and oral levosimendan and 2) the pharmacodynamics and pharmacokinetics of 
intravenous and oral levosimendan and its metabolites in patients with ischaemic heart disease. 
In the four studies included in this thesis levosimendan was administered intravenously or 
orally to 557 patients with ischaemic heart disease with or without concomitant heart failure. 
Study I included patients with acute myocardial infarction, complicated by left ventricular 
failure. Studies II to IV included patients with chronic ischaemic heart disease; in studies II and 
IV the ischaemic heart disease was complicated by severe chronic heart failure. Non-invasive 
haemodynamic measurements were used in all studies, and blood samples were drawn for 
pharmacokinetic evaluation in studies II to IV. Safety of the patients was followed by ECG 
recordings, adverse event inquiries and laboratory assessments. 
Intravenous levosimendan, administered as a 6-hour infusion in doses of 0.1 or 0.2 µg/kg/min 
did not cause clinically significant hypotension or ischaemia in comparison with placebo and 
reduced worsening heart failure and short- and long-term mortality. Increase in incidence of 
hypotension and ischaemia was seen with a dose of 0.4 µg/kg/min. Both intravenous and oral 
levosimendan possessed a moderate positive inotropic effect. Vasodilatory effect was more 
pronounced with intravenous levosimendan. A chronotropic effect was seen in all studies; 
however, it was not accompanied by any increase in arrhythmic events. The formation of 
levosimendan metabolites after oral dosing increased linearly with the daily dose of the parent 
drug, leading to increased inotropic and chronotropic response, especially with the doses of 6 
and 8 mg daily. Levosimendan was well tolerated in all studies. 
In conclusion, levosimendan was safe and effective in the treatment of patients with acute and 
chronic ischaemia. The risk-benefit ratio of intravenous levosimendan is favourable up to the 
dose of 0.2 µg/kg/min. The daily dose of oral levosimendan in patients with ischaemic heart 
failure should not exceed 4 mg due to an increase in chronotropic response. 
 5 
CONTENTS 
LIST OF ORIGINAL PUBLICATIONS .................................................................................................6 
ABBREVIATIONS...........................................................................................................................7 
1. INTRODUCTION ......................................................................................................................9 
2. REVIEW OF THE LITERATURE................................................................................................10 
2.1 Pathophysiological features of ischaemic heart disease......................................................... 10 
2.2 Consequences of myocardial ischaemia................................................................................. 13 
2.3 Clinical presentation of ischaemic heart disease .................................................................... 15 
2.4 Therapy of IHD ...................................................................................................................... 19 
2.5 Positive inotropic drugs in the treatment of ischaemic heart failure ...................................... 30 
2.6 Levosimendan ........................................................................................................................ 33 
3. AIMS OF THE STUDY.............................................................................................................45 
4. SUBJECTS AND METHODS....................................................................................................46 
4.1 Study subjects......................................................................................................................... 46 
4.2 Study designs ......................................................................................................................... 48 
4.3 Assessments ........................................................................................................................... 51 
4.4 Statistical methods ................................................................................................................. 56 
4.5 Ethics...................................................................................................................................... 57 
5. RESULTS.............................................................................................................................58 
5.1 Efficacy .................................................................................................................................. 58 
5.2 Pharmacokinetics ................................................................................................................... 65 
5.3 Safety...................................................................................................................................... 67 
6. DISCUSSION ........................................................................................................................70 
6.1 Study population .................................................................................................................... 70 
6.2 Background therapy ............................................................................................................... 70 
6.3 Haemodynamic effects........................................................................................................... 71 
6.4 Symptoms............................................................................................................................... 72 
6.5 Morbidity and mortality ......................................................................................................... 73 
6.6 Safety...................................................................................................................................... 74 
6.7 Feasibility of levosimendan in long-term treatment............................................................... 74 
7. LIMITATIONS OF THE STUDIES ..............................................................................................76 
8. SUMMARY AND CONCLUSIONS .............................................................................................77 
9. ACKNOWLEDGEMENTS ........................................................................................................78 
10. REFERENCES ......................................................................................................................79 
 
ORIGINAL PUBLICATIONS ..................................................................................................10  7
 6 
LIST OF ORIGINAL PUBLICATIONS 
I. Moiseyev VS, Põder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, 
Lehtonen LA, Laine T, Nieminen MS, Lie KI. Safety and efficacy of a novel calcium 
sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial 
infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 
2002;23(18):1422-32. 
II. Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken Ü, Rantanen S, 
Lehtonen L. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral 
levosimendan in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 
2003;41(8):365-73. 
III. Põder P, Eha J, Antila S, Heinpalu M, Planken Ü, Loogna I, Mesikepp A, Akkila J, 
Lehtonen L. Pharmacodynamic interactions of levosimendan and felodipine in patients with 
coronary heart disease. Cardiovasc Drugs Ther 2003;17(5-6):451-8. 
IV. Põder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Rantanen S, Lehtonen L. 
Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in 




ACC American College of Cardiology 
ACE angiotensin-converting enzyme 
ACS acute coronary syndrome 
ADP adenosine diphosphate 
ANOVA analysis of variance 
ANP atrial natriuretic peptide 
AMI acute myocardial infarction 
ARB angiotensin II receptor blocker 
ASA acetylsalicylic acid 
ATP adenosine triphosphate 
AUC area under concentration-time curve 
AV atrioventricular 
BNP b-type natriuretic peptide 
BP blood pressure 
CABG coronary artery by-pass grafting 
CCS Canadian Cardiovascular Society 
CO cardiac output 
cAMP cyclic adenosine monophosphate 
cGMP cyclic guanosine monophosphate 
CABG coronary artery by-pass grafting 
CHF chronic heart failure 
CI confidence interval 
CK creatine kinase 
CK-MB MB-fraction of creatine kinase 
Cltot total clearance 
Cmax maximum concentration 
COX cyclooxygenase 
CVD cardiovascular disease 
dBP diastolic blood pressure 
dp/dt rate of rise of intraventricular pressure 
DTI direct thrombin inhibitor 
ECG electrocardiogram 
eNOS endothelial NO synthase 
ESC European Society of Cardiology 
Gp glycoprotein 
HDL high density lipoprotein 
HMG-CoA hydroxylmethylglutaryl coenzyme A 
HR heart rate 
IHD ischaemic heart disease 
K+ATP channels ATP-sensitive potassium channels 
LDL low-density lipoprotein 
LMWH low molecular weight heparin 
LS levosimendan 
LVEF left ventricular ejection fraction 
LVD left ventricular dysfunction 
LVF left ventricular failure 
MMP matrix metalloproteinase 
MRT mean residence time 
 8 
NO nitric oxide 
NSTE ACS non ST-elevation acute coronary syndrome 
NSTEMI non ST-elevation myocardial infarction 
NYHA New York Heart Association 
PCI percutaneous coronary intervention 
PCWP pulmonary capillary wedge pressure 
PDE phosphodiesterase 
PEP primary endpoint 
PET positron emission tomography 
PKA protein kinase A 
PKC-ε protein kinase C-epsilon 
PTCA percutaneous transluminal coronary angioplasty 
QS2 electromechanical systole 
QS2i heart rate corrected electromechanical systole 
RAAS renin-angiotensin-aldosterone system 
Rt-PA recombinant tissue plasminogen activator 
sBP systolic blood pressure 
SD standard deviation 
SEM standard error of the mean 
STEMI ST-elevation myocardial infarction 
tmax time of maximum concentration 
t1/2 terminal elimination half-life 
TNFα tumour necrosis factor alpha 
UFH unfractionated heparin 
UA unstable angina 
VEGF vascular endothelial growth factor 
Vss apparent volume of distribution at steady-state 
VSMC vascular smooth muscle cell 
VT ventricular tachycardia 
Vz apparent volume of distribution based on the terminal phase 
WHO World Health Organisation 
λz terminal elimination rate constant 
 9 
1. Introduction 
Ischaemic heart disease (IHD) belongs to the entity of cardiovascular disease (CVD), together 
with hypertension, stroke and valvular, muscular and congenital heart disease. About 15% of 
worldwide mortality is attributable to IHD, making it the leading cause of death globally (1). 
By 2020 it is expected that IHD will be the largest cause of disease burden worldwide (2). In 
USA more than 12 million people currently suffer from IHD and in 2000 the economic cost of 
IHD was estimated at about 120 billion USD (3). 
Recent epidemiological data have shown that mortality due to IHD in industrialised countries is 
decreasing (4). The reasons for such a decrease include the introduction of new treatment 
measures and the reduction in the incidence of the major risk factors of IHD 
(hypercholesterolemia, hypertension, diabetes and smoking). For example in USA the mortality 
due to IHD has declined by 50% over the last 30 years (5). Similar trends have been observed 
also in other Western countries (4, 6). 
Current therapy of IHD consists of pharmacological therapy and revascularisation procedures. 
The main goals of these treatment measures are establishing reperfusion in coronary arteries, 
enhancing coronary blood flow, reduction of myocardial oxygen consumption and the incidence 
of arrhythmic disorders and, in patients with acute myocardial infarction (AMI), also limitation 
of the infarct size. IHD is the most important and most common contributor to the development 
of heart failure, accounting for up to 50% of cases (7, 8). The prognosis of patients with heart 
failure due to IHD remains poor despite intensive pharmacological therapy and increasing 
utilization of surgical interventions.  
Treatment with positive inotropic drugs is currently indicated for patients with severe chronic 
or acute heart failure to improve the pump function of the heart (7, 9, 10). Beta-adrenergic 
agonists and phosphodiesterase inhibitors improve cardiac contractility by increasing 
intracellular calcium concentration. This mechanism, however, leads to increase in myocardial 
oxygen consumption. Increase in oxygen demand further leads to the increase of arrhythmic 
and ischaemic complications, which can easily occur in ischaemic patients, whose 
haemodynamics is unstable. Therefore these drugs have not been widely used in patients with 
current or recent ischaemia. Furthermore, clinical trial evidence regarding positive inotropic 
drugs in these patients is very limited (10-13). 
Levosimendan is a drug that possesses a novel mechanism of positive inotropy. It is a calcium 
sensitizer, meaning that the drug augments myocardial contractility by increasing myofilament 
sensitivity to calcium by binding to cardiac troponin C in a calcium-dependent manner (14-17). 
This mechanism allows the achievement of positive inotropic effect without increasing 
intracellular calcium concentrations. Levosimendan also opens ATP-sensitive potassium 
channels (K+ATP) in vascular and cardiac tissue, thereby producing vasodilatory and possibly 
also anti-ischaemic effects (18-20). Levosimendan inhibits also cardiac and smooth muscle 
phosphodiesterase, being a phosphodiesterase (PDE) III inhibitor (21). 
Previous studies have shown that levosimendan does not significantly increase myocardial 
oxygen consumption in healthy volunteers or in patients with heart failure (22, 23). In theory 
levosimendan may therefore be safer than conventional inotropes in patients with acute or 
chronic ischaemia. 
The aim of this thesis was to study the effects of levosimendan in patients with stable IHD or 
AMI, with and without concurrent heart failure. 
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2. Review of the literature 
2.1 Pathophysiological features of ischaemic heart disease 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory condition, together with endothelial dysfunction, 
which advances to a clinical event by the formation of atherosclerotic plaques and the induction 
of plaque rupture, which leads to thrombosis (24-26). Endothelial dysfunction is considered an 
early marker for atherosclerosis, preceding angiographic or ultrasonic evidence of 
atherosclerotic plaque formation. Damage to the endothelium upsets the balance between 
vasoconstriction and vasodilation and initiates the processes that promote or exacerbate 
atherosclerosis; these include endothelial permeability, platelet aggregation and generation of 
cytokines (27, 28). The hallmark of endothelial dysfunction is impairment of the nitric oxide-
mediated vasodilation. 
Role of nitric oxide (NO) in atherosclerosis and ischaemia 
NO is formed in endothelial cells from its precursor L-arginine via the enzymatic action of 
endothelial NO synthase (eNOS) (29). In the vascular wall, NO activates soluble guanylate cyclase 
in vascular smooth muscle cells (VSMCs), leading to elevation of cyclic guanosine monophosphate 
(cGMP), activation of cGMP-dependent protein kinase (PKG), and vasorelaxation (30). It has been 
proposed that oxidation of low-density lipoprotein (LDL) is a major mechanism of atherosclerosis 
(26). Since NO prevents oxidative modification of LDL, impaired production or activity of NO 
leads to events that promote atherosclerosis, such as vasoconstriction, platelet aggregation, smooth 
muscle cell proliferation and migration, leukocyte adhesion and oxidative stress (27). Oxidized 
LDL cholesterol increases the synthesis of caveolin-1, which by inactivating eNOS, inhibits 
production of NO (31). In patients with dysfunctional endothelium, the loss of flow-mediated and 
catecholamine-stimulated NO release permits the vasoconstriction by catecholamines. Thus the 
reduced production of NO contributes to impaired vasodilation and exaggerated coronary 
vasoconstriction and thereby also to myocardial ischaemia (32-34). 
In the later stages of atherosclerosis ultrastructural changes will take place. Atherosclerotic 
plaque formation starts with the development of a fatty streak. Several phases can be identified 
in streak development, e.g. extracellular lipid formation, leukocyte accumulation and foam cell 
and lesion formation (26, 35). In the next phase of evolution of the atheroma - development of a 
fibrofatty lesion - smooth muscle cells divide and elaborate extracellular matrix, promoting 
extracellular matrix accumulation in the growing atherosclerotic plaque (36, 37). In addition, 
neovascularization occurs in atherosclerotic plaques (38). During the progress to advanced 
lesions, fatty streaks tend to form a fibrous cap that walls off the lesion to lumen. In the 
beginning the plaque grows outwards, leading to an increase in the diameter of the artery. At 
some point when the artery can no longer compensate by dilation, the lesion intrudes into the 
lumen and alters blood flow (39, 40). 
The late stages are marked by calcification and rupture of the plaque. Calcification is promoted 
by smooth muscle cells, by enhanced secretion of bone morphogenetic proteins, which suggests 
that plaque calcification can be regulated similarly to bone formation (41, 42). Plaque rupture, 
which is the predominant cause of thrombosis, can be defined as a disruption of an area of the 
fibrous cap, whereby the overlying thrombus is in continuity with the lipid core (43). Plaques 
with active inflammation, thin cap with large lipid core, endothelial denudation with superficial 
platelet aggregation, and plaques with fissured caps and stenotic plaques, are considered to be 
“vulnerable” plaques (44, 45). Another process leading to thrombosis is called endothelial 
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erosion. In this case the plaque itself is intact. The erosion is caused by an extension of the 
process of endothelial denudation whereby large areas of the surface of the subendothelial 
connective tissue of the plaque are exposed (46, 47). 
The rupture of plaques is considered to be the common pathophysiological substrate of acute 
coronary syndromes (ACS), involving unstable angina (UA), and transmural (STEMI) and non-
transmural myocardial infarction (NSTEMI). When episodes of stable angina are associated 
with plaque rupture associated with intraplaque thrombus, then UA is associated with thrombi 
that project, but do not occlude the lumen of the coronary artery, thus preserving some 
antegrade flow in the artery. Several potential mechanisms of UA attacks, such as constriction 
of coronary artery, intermittent change in size of thrombus and platelet disposition, have been 
proposed. Acute myocardial infarction (AMI), on the other hand, occurs when total coronary 
artery occlusion develops. In case of transmural (STEMI) infarction, occlusion develops over a 
relatively short time frame of a few hours and persists for at least 6-8 hours. The infarcted tissue 
is a structurally homogenous entity, i.e. all the involved myocardium dies at around the same 
time. Non-transmural (NSTEMI) infarcts have a different structure, built up by the coalescence 
of many small areas of necrosis of very different ages. A factor in limiting the spread of 
necrosis and preserving the subepicardial zone is the existence of collateral flow in the affected 
artery. The development of AMI results in apoptosis and necrosis of myocardiocytes (46). 
Apoptosis and necrosis 
The common view on how cardiomyocytes die during or after myocardial ischaemia or 
infarction has changed in recent years. For a long time necrosis was regarded as the sole cause 
of cell death. Now recent studies indicate that also apoptosis plays an important role in the 
process of tissue damage. Although both apoptosis and necrosis result in the death of the cell, 
they differ regarding several morphological and cellular regulatory features (48). 
Necrosis is characterised by the rapid loss of cellular homeostasis, rapid swelling as a result of 
the accumulation of water and electrolytes, early plasma membrane rupture and disruption of 
cellular organelles (48). Different patterns of necrosis have been described. Coagulation 
necrosis, resulting from severe, persistent ischaemia, is present usually in the central region of 
infarction. The coagulation necrosis results in the arrest of muscle cells in the relaxed state and 
is characterised by shrinkage and loss of nucleus (49). The other form, contraction band 
necrosis, results primarily from severe ischaemia followed by reflow (reperfusion). It is caused 
by calcium ion influx into dying cells, resulting in the arrest of cells in the contracted state and 
is characterised by contracted myofibrils in contraction bands and mitochondrial damage with 
calcification and vascular congestion (49). 
Apoptosis was first introduced in a paper by a group of pathologists studying cell population 
regulation (50). Apoptosis is defined as a form of cell death that involves genetic and molecular 
programs, de novo protein expression and unique cellular phenotype (48, 51, 52). It is 
characterised by shrinkage of the cell and nucleus. Nuclear chromatin is condensed into sharply 
delineated masses and eventually breaks up. Then the cell detaches from the surrounding tissue. 
At this stage, extensions bud out from its membranes, which seal off to form membrane 
enclosed vesicles, called apoptotic bodies, containing condensed cellular organelles and nuclear 
fragments. These apoptotic bodies are either rapidly phagocytosed by neighbouring cells or 
undergo degradation, which resembles necrosis in a process called secondary necrosis. In 
contrast to necrosis, apoptosis is generally considered not to trigger an inflammatory response 
(48, 51-53). 
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In the cardiovascular system apoptosis has been found in addition to AMI also in association 
with dilative cardiomyopathy and conduction system disorders (54-56). Apoptosis is also a 
feature of atherosclerosis, evidenced by increased expression of molecular markers in 
atherosclerotic tissue (57, 58). Multiple studies have found apoptosis in atherosclerotic 
coronary, carotid and aortic arteries and in smooth muscle cells of the media underlying 
atherosclerotic lesions (58-60). 
Several stimuli and pathways that elicit cardiomyocyte apoptosis have been identified. They 
include ischaemia (especially when followed by reperfusion) (61, 62), oxygen radicals (H2O2, 
O2-) (63), caspases (64), tumour necrosis factors (65, 66), and nuclear factor-kappaB (67). 
Three consequences of cardiomyocyte apoptosis and necrosis can be envisioned: 
1) compromise in cardiac contractility due to loss of myocytes; 
2) conduction disturbances leading to arrhythmias; 
3) cardiac remodelling due to disruption of the geometrical alignment of myocytes. 
Cardiac remodelling 
Cardiac remodelling is the central mechanism of heart failure progression in patients with IHD, 
occurring usually as a consequence of AMI. Postinfarction remodelling can be divided into an 
early phase (within 72 hours) and a late phase (beyond 72 hours) (68). 
Early remodelling 
Early remodelling involves expansion of the infarct zone and collagen degradation, which may 
result in early ventricular rupture or aneurysm formation (69). Infarct expansion results from 
the degradation of the intermyocyte collagen struts by serine proteases and from the activation 
of matrix metalloproteinases (MMPs) released from neutrophils (70). Infarct expansion occurs 
within hours of myocyte injury, results in wall thinning and ventricular dilatation, and causes 
the elevation of diastolic and systolic wall stresses (71). Substantial changes in circulatory 
haemodynamics trigger the sympathetic adrenergic system, which stimulates catecholamines, 
activates the renin-angiotensin-aldosterone system (RAAS), and stimulates the production of 
endothelins, and atrial and b-type natriuretic peptides (ANP and BNP). Positive inotropic, 
chronotropic and also vasodilatory effects from this sympathetic stimulation result in 
hyperkinesis of the noninfarcted myocardium and temporary circulatory compensation by 
reduction of systemic vascular resistance and left ventricular filling pressure (68). However, 
although the neurohormonal activation initially serves an adaptive role, in later stages the 
responses become pathological and contribute adversely to remodelling and ultimately to the 
progress of heart failure. In addition, neurohormonal activation may precipitate further 
ischaemia by increasing oxygen demand and predisposing to arrhythmias (72). 
Late remodelling and scar formation 
Late remodelling involves the left ventricle globally and is associated with time-dependent 
dilatation, distortion of ventricular shape and hypertrophy. Hypertrophy is an adaptive response 
during postinfarction remodelling that offsets increased load, attenuates progressive dilatation, 
and stabilizes contractile function (73). It is initiated by neurohormonal activation, myocardial 
stretch, activation of the RAAS, and by paracrine/autocrine factors. Especially enhanced 
norepinephrine release contributes to the hypertrophy. 
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Myocardial repair and scar formation is triggered by cytokines released from injured myocytes. 
Before collagen synthesis tissue repair is initiated by the formation of a fibrin-fibronectin 
matrix to which myofibroblasts become adherent (74). Deposition of collagen occurs 
predominantly in the infarct zone, but also in noninfarcted myocardium. Collagen is detectable 
microscopically by day 7 and its deposition then increases dramatically, such that by 28 days, 
the necrotic myocytes are entirely replaced by fibrous tissue. After the formation of a scar that 
equilibrates distending and restraining forces, collagen formation is down-regulated and most 
fibroblasts undergo apoptosis (70). 
2.2 Consequences of myocardial ischaemia 
Myocardial stunning and hibernation 
After a brief episode of severe ischaemia, there is a period of prolonged myocardial dysfunction 
with a gradual return of contractile activity. This condition has been termed as myocardial 
stunning (75). Myocardial stunning has been observed in patients with IHD in a variety of 
clinical conditions, such as early thrombolytic reperfusion after AMI, percutaneous 
transluminal coronary angioplasty (PTCA), delayed recovery from angina pectoris and 
ischaemic cardioplegia in connection with coronary artery by-pass grafting (CABG) (76-78). 
Stunning is currently considered to occur via three synergic mechanisms: 
a) generation of oxygen derived free radicals 
b) increase of cytosolic calcium and reduction in sensitivity of myofilaments to calcium 
c) loss of myofilaments (79). 
In case of stunning, myocardial ischaemia, followed by reperfusion, results in increased 
production of superoxide and hydroxyl radicals, the targets of which are sarcolemmal Na+ K+ - 
and Ca2+-stimulated ATPase and in sarcoplasmatic reticulum Ca2+-stimulated ATPase. This 
causes increased influx of calcium through sarcolemma and decreased calcium reuptake by 
sarcoplasmatic reticulum, which results in cellular calcium overload and impaired excitation-
contraction coupling. Ischaemia followed by reperfusion results in decreased calcium 
sensitivity of myofilaments. Recovery from stunning takes from hours to days, depending on 
the duration of the occlusion. Full mechanical recovery from stunning may take from days to 
weeks (76-78). 
The term myocardial hibernation was introduced in the early 1980s; it refers to the presence of 
impaired left ventricular function due to reduced coronary blood flow that can be improved by 
revascularisation (80, 81). The molecular basis of hibernation has not been extensively 
investigated so far. It has been shown that hibernating myocardium exhibits a molecular 
phenotype that on a regional basis is similar to that found in end-stage ischaemic 
cardiomyopathy (82). There is evidence that hibernation is related to partial inhibition of 
cytochrome oxidase during hypoxia, which allows mitochondria to function as the oxygen 
sensors, limiting ATP utilization and oxygen consumption (83). A recent study has also 
demonstrated the upregulation of genes and corresponding proteins involved in anti-apoptosis 
(IAP, caspase inhibitor), growth (VEGF, vascular endothelial growth factor) and cytoprotection 
(hypoxia-inducible factor -1α, heat-shock protein HSP70) (84). 
Hibernating myocardium is present in approximately one third of patients with IHD and 
impaired left ventricular function (85, 86). The time course of recovery of hibernating 
myocardium after revascularisation varies from days to months. In many cases, however, 
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recovery remains incomplete (87). Detection of hibernating myocardium is based on finding 
still viable akinetic or hypokinetic segments of left ventricle. Different methods are used for 
detection of myocardial viability and contractile reserve, e.g. dobutamine stress 
echocardiography, thallium-201 redistribution study, imaging with technetium-99m-sestamibi 
and positron-emission tomography (88). 
Both stunning and hibernation play an important clinical role, since they contribute to the 
process and progress of heart failure in patients with IHD. A major unresolved issue that has 
important pathophysiological and clinical implications is whether repetitive episodes of 
myocardial stunning can account for at least some of the clinical manifestations of hibernation. 
Indeed, it has been demonstrated that recurrent stunning can cause prolonged, reversible 
dysfunction. The main difference between stunning and hibernation is that regional perfusion is 
normal or near normal in stunning, but low in hibernation. If regional perfusion is not measured 
simultaneously with regional contractile function (and it is rarely done in clinic), the reversible 
dysfunction associated with repetitive stunning may mimic hibernation. On the other hand, it is 
well known that many patients with IHD experience recurrent episodes of ischaemia in the 
same territory, so the myocardium may remain reversibly depressed for extended periods of 
time. It is therefore possible that in some clinical cases in which reversible left ventricular 
dysfunction is thought to be secondary to hibernation, the depressed contractility is in fact 
secondary to repetitive stunning (89). 
The treatment of these two forms of myocardial dysfunction is different. Several trials have 
demonstrated that patients with hibernating myocardium with left ventricular dysfunction 
appear to have better outcome after revascularisation (90-92). Myocardial stunning, on the other 
hand, can be reversed by using positive inotropic agents. Positive inotropic drugs have been 
useful in the post-cardiopulmonary by-pass setting and in patients who experience severe heart 
failure after successful reperfusion (93-95). Since one of the mechanisms of stunning is 
desensitization of myofilaments to calcium, an inotrope that would increase the sensitivity of 
myofilaments, would in theory be a very useful pharmacological tool to overcome stunning. 
Ischaemic preconditioning 
Myocardial ischaemic preconditioning is a phenomenon by which the brief episodes of 
myocardial ischaemia increase the ability of the heart to tolerate a subsequent period of 
ischaemic injury. The stimulus for preconditioning is the reduction of coronary blood flow. The 
protection obtained has been characterized both in terms of time course and various end points 
in cellular injury (96). Preconditioning has been shown to reduce reperfusion arrhythmias (97), 
slow energy metabolism during early stages of ischaemia (98), improve post-ischaemic 
recovery of function (99), protect coronary endothelium (100), and increase the resistance of 
isolated myocytes to hypoxia (101) and ischaemia (102). 
Preconditioning can be divided according to its time course to “early” and “late” 
preconditioning (96). Typically in early preconditioning, a 5-minute period of ischaemia 
followed by up to 60-minute reperfusion prior to the repeat ischaemic episode results in salvage 
(103). If the time between the initial and repeated ischaemia is prolonged to 24-96 h, a 
protective effect may also be seen and is called as late preconditioning (104). Unlike the early 
preconditioning the late preconditioning protects against not only myocardial infarction, but 
also against myocardial stunning (105). 
Adenosine and bradykinin are the most well-studied triggers of preconditioning (106, 107). The 
protective effect of ischaemic preconditioning is thought to be due to intracellular mediators, 
three types of which have been described in literature: K+ATP channels, protein kinase C-epsilon 
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(PKC-ε) and protein kinase A (PKA) (108-110). Two K+ATP channels exist in different locations 
in cardiomyocytes: in the sarcolemma and the mitochondria. K+ATP channels open whenever 
ATP declines substantially, as during brief ischaemic periods (111). Blocking the K+ATP 
channel eliminates the preconditioning effect (112, 113). Sarcolemmal K+ATP channels can be 
blocked by sulfonylureas and 5-hydroxycanoate (5HD), whereas mitochondrial K+ATP channels 
can be opened by diazoxide and blocked with low concentrations of 5HD (96, 113). It is 
suggested that the lack of cardioprotective effect by sulfonylureas may be due to blunting of the 
K+ATP channel dependent component of the preconditioning response (114). The protein kinases 
play a role in preconditioning possibly through kappa-opioid receptors, Rho-kinase inhibition 
and actin cytoskeletal deactivation (110). For late preconditioning, also additional stimuli, 
including heat stress, rapid ventricular pacing, exercise, endotoxins, interleukin-1, TNFα, 
reactive oxygen species, NO donors and adenosine receptor agonists have been proposed (96). 
Ischaemic preconditioning has also important clinical implications. It has been shown that 
preinfarction angina is associated with a subsequent reduction of the infarct size (115, 116). 
Ischaemic preconditioning is also responsible for the “warm up” or “walk through angina” 
phenomenon, and it has been shown to protect against ventricular tachyarrhythmias following 
balloon occlusion in PTCA, in variant angina and following CABG (117, 118). Administration 
of drugs that induce or enhance ischaemic preconditioning have therefore potential to decrease 
myocardial injury, cell death, preserve ventricular function and reduce mortality. Such agents 
could include adenosine and its agonists, PKC agonists, NO donors and K+ATP openers. 
2.3 Clinical presentation of ischaemic heart disease 
Ischaemic heart disease is caused by an imbalance between the supply and demand of oxygen 
to the heart. The condition is most often caused by the narrowing of coronary arteries and an 
associated reduction in the flow of oxygenated blood. The disease may be symptomatic or 
asymptomatic and it may have a stable or a progressive course. IHD is classified on the basis of 
symptomatology and severity (119-122). 
Stable angina pectoris 
Stable angina pectoris is the main symptom/form of IHD. The pathological substrate for angina 
is almost invariably atheromatous narrowing of the coronary arteries. It is usually considered 
that a coronary artery must be narrowed by at least 50-70% in luminal diameter before coronary 
blood flow is inadequate to meet the metabolic demands of the heart with exercise or stress 
(120-122). The importance of stenosis depends also on the length and number of stenoses. 
Angina pectoris results from myocardial ischaemia, which is caused by an imbalance between 
myocardial oxygen requirements and oxygen supply. Increased oxygen demand may occur due 
to increase in heart rate, left ventricular wall stress or contractility. Oxygen supply, on the other 
hand, is determined by coronary blood flow and coronary arterial oxygen content. The 
precipitating factors causing angina due to increased myocardial oxygen consumption include 
exercise, mental stress, fever, cold, tachycardia from any cause, thyrotoxicosis, and 
hypoglycaemia (123). Typical angina pectoris is substernal, across mid-thorax, anteriorly, can 
locate also in arms, shoulders, neck, and interscapular region. It is characterized by a burning, 
heavy or squeezing feeling, is precipitated by exertion or emotion and is promptly relieved by 
rest or by nitroglycerin. The typical episode of angina pectoris usually begins gradually and 
reaches its maximum intensity over a period of minutes before dissipating (119-122, 124). If the 
symptoms remain the same for several weeks and constantly occur under the same physical or 
mental stress, the condition is described as “stable” angina pectoris (119-122). 
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Stable angina pectoris is classified by severity into 4 classes according to the Canadian 
Cardiovascular Society (125, 126) (Table 1). 
Table 1. Classification of stable angina pectoris 
Class I Angina occurs with strenuous or rapid or prolonged exertion at work or recreation. 
Ordinary physical activity, such as walking and climbing stairs, does not cause angina.  
Class II Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs 
rapidly, walking uphill, walking or stair climbing after meals, in cold, in wind or when 
under emotional stress, or only during the few hours after awakening. Walking more than 
two blocks on the level and climbing more than one flight of ordinary stairs at a normal 
pace and in normal conditions. 
Class III Marked limitation of ordinary physical activity. Walking one to two blocks on the level 
and climbing more than one flight in normal conditions. 
Class IV Inability to carry on any physical activity without discomfort – anginal syndrome may be 
presented at rest. 
Unstable angina pectoris and Prinzmetal (variant) angina 
The currently used definition of unstable angina pectoris depends on the presence of one or 
more of the following features: 
1) Crescendo angina (more severe, prolonged or frequent) superimposed on an existing 
pattern of relatively stable, exertion-related angina pectoris 
2) Angina pectoris of new onset (usually within 1 month), which is brought on by minimal 
exertion 
3) Angina pectoris at rest as well as with minimal exertion (119). 
A classification of UA is presented in Table 2 (127). 
Table 2. Classification of unstable angina pectoris 
 Class I New-onset, severe or accelerated angina. Patients with angina of less than 2 months’ duration, 
severe angina or angina occurring three or more times per day or angina that is distinctly more 
frequent and precipitated by distinctly less exertion. No rest pain in the last 2 months. 
Class II Angina at rest. Subacute. Patients with one or more episodes at rest during the preceding month, 
but not within the preceding 48 hours. 
Class III Angina at rest. Acute. Patients with one or more episodes at rest within the preceding 48 hours. 
Prinzmetal’s (variant) angina is an unusual and uncommon form of angina secondary to 
myocardial ischaemia that occurs almost exclusively at rest, is usually not precipitated by 
physical exertion or emotional stress and is associated with ST-segment elevations in 
electrocardiogram (128-130). Variant angina is demonstrated to be due to coronary artery 
spasm, which narrows the coronary artery resulting in myocardial ischaemia (129, 130). 
Endothelial dysfunction, an increased platelet aggregation together with changes in autonomic 
tone can trigger the vasospasms (131, 132). Also dysfunction of K+ATP channels may have role 
in variant angina (133). 
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Silent ischaemia 
Silent myocardial ischaemia is defined as objective documentation of myocardial ischaemia in 
the absence of angina or anginal equivalents. It has been explained by the ability of patients to 
produce endogenous opioids that raise the pain threshold, by autonomic neuropathy and also by 
a defect in the cerebral cortex. Silent ischaemia and infarction are more frequent in the elderly, 
women and diabetics (134). Patients with silent ischaemia can be divided into three types: Type 
I patients have no symptoms at any time in spite of obstructive IHD, type II patients have silent 
ischaemia after experiencing AMI, and patients of type III, the most common group, have either 
concurrent chronic stable angina, UA or Prinzmetal angina (134). Patients experiencing 
episodes of silent myocardial ischaemia have been found to have a worse prognosis compared 
with those without silent ischaemia (135-138). 
Acute myocardial infarction 
Acute myocardial infarction (AMI) represents the most critical and serious form of IHD. 
Although the death rate from AMI has continuously declined over the past decades, its 
development together with all complications is fatal for about one third of the patients (139, 
140). 
Almost all AMIs result from coronary atherosclerosis, generally with superimposed coronary 
thrombosis. During the natural evolution of atherosclerotic plaques an abrupt transition may 
occur, characterized by plaque rupture. After plaque rupture there is an exposure of substances 
that promote platelet activation and aggregation, thrombin generation and ultimately thrombus 
formation. The thrombus interrupts the blood flow and leads to an imbalance between oxygen 
supply and demand and, if this imbalance is severe and persistent, to myocardial necrosis. After 
onset of infarction, the first ultrastructural changes are noted already within 20 minutes. The 
first irreversible changes are seen after about 1-2 hours from onset of AMI. After about 6 hours 
of continuous occlusion the entire jeopardised area becomes necrotic. The infarction process 
results in the formation of a fibrous scar with interspersed intact muscle fibres after about 6 
weeks from onset of the process (140). 
The WHO criteria for diagnosis of AMI required that at least two of three elements be present 
for diagnosis; these criteria have been used for several decades for diagnosis of AMI (141). 
Recently, however, mainly for purposes of risk stratification and subsequent treatment, a 
revised definition of AMI has been proposed by European and American cardiology societies 
(Table 3) (142). 
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Table 3. Diagnostic criteria of acute myocardial infarction  
WHO  1) Definite ECG or 
2) Typical or atypical symptoms or inadequately described symptoms, together with probable 
ECG or abnormal enzymes or 
3) Typical symptoms with abnormal enzymes with ischaemic or non-codable ECG or ECG not 
available or 
4) Fatal case, whether sudden or not, appearance of fresh myocardial infarction and/or recent 
coronary occlusion found at necropsy  
ESC and 
ACC 
1) Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical 
markers of myocardial necrosis with at least one of the following: 
a) ischaemic symptoms 
b) development of pathological Q-waves on ECG 
c) ECG changes indicative of myocardial ischaemia (ST-segment elevation or depression) 
d) coronary artery intervention (e.g. coronary angioplasty) 
 2) Pathological findings of an AMI 
Heart failure and cardiogenic shock 
Heart failure is a syndrome in which patients should have the following features: symptoms of 
heart failure (typically breathlessness or fatigue, either at rest or during exertion, or ankle 
swelling), and objective evidence of cardiac dysfunction (7). The clinical symptoms and signs 
of heart failure also include hepatojugular reflux, jugular venous distension, gallop rhythm, 
proteinuria, pulmonary rales, cyanosis and ascites. In addition, B-type natriuretic peptide, a 
protein released from the left ventricle in response to volume expansion and pressure overload, 
has been recently introduced as the first blood marker for identification of patients with heart 
failure (143, 144). Most heart failure is associated with left ventricular systolic dysfunction. 
Diastolic heart failure is diagnosed when symptoms and signs of heart failure occur in the 
presence of normal systolic function (7, 9). 
IHD is considered to be the commonest cause of systolic dysfunction and heart failure in the 
current era (7, 9). Despite different new treatment initiatives, heart failure in its different 
clinical forms has remained the most common cause of death in patients with IHD. Three main 
underlying mechanisms of heart failure can be identified in patients with IHD: 
1) Permanent myocyte loss due to infarction with scar formation 
2) Chronic dysfunction in viable myocardium subtended by stenosed coronary arteries which 
recovers after revascularisation (hibernating myocardium) 
3) Changes in the remote myocardium (adverse remodelling) (145). 
Table 4 shows the New York Heart Association (NYHA) classification of chronic heart failure, 
which is based on the relation between symptoms and the effort to provoke them (146). 
Table 4. NYHA classification of chronic heart failure 
Class I Ordinary physical activity does not cause symptoms. 
Class II Slight limitation of physical activity. Ordinary physical activity results in symptoms. 
Class III Marked limitation of physical activity. Less than ordinary physical activity leads to symptoms. 
Class IV Inability to carry on any physical activity without discomfort. Symptoms of heart failure are 
present at rest. With any physical activity, increased discomfort is experienced. 
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In patients with chronic angina, heart failure often develops over time, i.e. the symptoms and 
worsening of NYHA heart failure class progress together with the progression of symptoms of 
IHD. However, the acute worsening of current IHD status may provoke rather rapid onset of 
symptoms and signs, a status defined as acute heart failure. There can be two clinical 
presentations – acute decompensated heart failure (“acute-on chronic”) or de novo acute heart 
failure. Both are characterised by rapid development of severe left ventricular failure and 
pulmonary oedema. However, whereas acute decompensated heart failure is characterised also 
by increased fluid retention (increased peripheral oedema), de novo acute heart failure usually 
occurs without clinical signs of peripheral oedema. Very often de novo acute heart failure 
occurs in patients with AMI, the severity being highly dependent on the extent of damage to the 
myocardium (10). A classification of heart failure after AMI, based on physical signs, was first 
published in 1967 by Killip and colleagues. It has proved useful for clinical characterisation and 
prognosis of these patients (Table 5) (147-149). 
Table 5. Killip classification of heart failure after AMI 
Class I No signs of congestive heart failure 
Class II S3 gallop and bibasilar rales 
Class III Acute pulmonary oedema 
Class IV Cardiogenic shock  
The most severe expression of acute heart failure is cardiogenic shock, which is associated with 
extensive damage to the left ventricular myocardium. Cardiogenic shock occurs when more 
than 40% of the myocardium is destroyed; it is observed in about 5-10% of patients with AMI 
and it is more common in patients with ST-elevation. Cardiogenic shock is characterized by 
marked and persistent hypotension with systolic blood pressure (sBP) less than 90 mmHg (or in 
chronically hypertensive patients a drop in sBP of 30 mmHg or more), reduced cardiac index, 
elevated pulmonary capillary wedge pressure (PCWP) and evidence of vital organ 
hypoperfusion (oliguria, cool extremities, acidosis). The timing of shock varies, but it occurs 
most commonly within 48 hours of the onset of AMI (150). 
A recent observational study in USA, carried out in 775 hospitals has revealed some decline in 
overall in-hospital cardiogenic shock mortality, which is probably related to more aggressive 
use of revascularization procedures. Mortality, however, remains high, being about 50% (151). 
2.4 Therapy of IHD 
2.4.1 Therapy to improve prognosis 
Beta-adrenergic receptor blockers 
Beta-adrenergic receptor blockers constitute a cornerstone of IHD therapy. The action of beta-
blockers depends on their ability to cause competitive inhibition of the effects of 
catecholamines on beta-receptors, which reduces myocardial oxygen requirements by slowing 
the heart rate, increasing the time for coronary perfusion and by reducing blood pressure. Thus, 
in case of impaired myocardial perfusion beta-blockers favorably alter the imbalance between 
oxygen supply and demand, thereby eliminating ischaemia (120-122, 152). Beta-blockers can 
be divided into three classes: 1) nonselective beta1 and beta2 receptor blockers (such as 
propranolol), 2) selective beta1 receptor blockers (such as metoprolol and atenolol), and 3) beta-
blocker-vasodilators (such as carvedilol and bucindolol) (120-122). 
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The efficacy of beta-blockers has been shown in numerous clinical trials in patients with stable 
angina, given either alone or together with other antianginal agents (153-158). Efficacy has 
been similar to that seen with calcium antagonists and nitrates, however, beta-blockers have had 
better tolerability (159, 160). The effect of beta-blockers on the prognosis of stable angina has 
not been established, although in UA several trials have shown benefit of beta-blockers in 
reducing the incidence of subsequent AMI or recurrent ischaemia (161-164). 
The benefit of using beta-blockers after AMI has been confirmed in well-controlled randomized 
clinical trials (Table 6). Use of beta-blockers undoubtedly improves both short- and long-term 
outcome, reduces the infarct size and is effective in the long-term secondary prevention of AMI 
(165-170). 
Beta-blockers were contraindicated for several years in patients with heart failure. However, 
well-controlled large randomized trials, such as the CIBIS II, MERIT-HF and COPERNICUS 
trials have now established their beneficial effect on mortality, which has been reduced by 
approximately one third in this population (171-173) (Table 6). The most extensively studied 
beta-blocker in this respect has been carvedilol, which has shown benefit over metoprolol 
(174). CAPRICORN and CHRISTMAS trials showed beneficial effects of carvedilol also in 
patients with IHD complicated by left ventricular dysfunction (LVD) (86, 175).  
Table 6. Major clinical trials with beta-blockers  




ISIS-1 (166) 16027 AMI atenolol placebo vascular mortality ↓ by 15% 
MERIT-HF 
(172) 
3991 NYHA II-IV metoprolol placebo all-cause mortality ↓ by 34% 
COMET (174) 3029 NYHA II-IV carvedilol metoprolol 1) all-cause mortality 
2) all-cause mortality 
or hospitalisation for 
any reason 
1) ↓ by 17% 
2) ↓ by 6% 
BEST (176) 2708 NYHA III-IV bucindolol placebo all-cause mortality ↓ by 10% 
CIBIS II (171) 2647 NYHA III-IV bisoprolol placebo all-cause mortality ↓ by 34% 
COPERNICUS 
(173)  
2289 Severe HF carvedilol placebo all-cause mortality ↓ by 35% 
CAPRICORN 
(175)  
1959 LVD after AMI carvedilol placebo all-cause mortality or 
CV hospitalisation 
↓ by 8% 
CHRISTMAS 
(86) 
387 CHF due to 
ischaemic LVD 
carvedilol placebo LVEF ↑ by 3% 
In summary, based on their effects on morbidity and mortality, beta-blockers should strongly be 
considered as initial therapy of all forms of IHD, including its complications, such as heart 
failure and arrhythmias. 
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers 
Angiotensin-converting enzyme (ACE) inhibitors have been in clinical use from the 1970s. 
They inhibit the enzyme that converts the inactive angiotensin I to active angiotensin II and 
they also inhibit bradykinin degradation. The main effect resulting from this mechanism is the 
prevention of cardiac remodelling as shown in different animal models of AMI and heart failure 
(177, 178). 
ACE inhibitors have been widely used for the treatment of hypertension and chronic heart 
failure (7). Recently their effects have been investigated in patients with chronic IHD (Table 7). 
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In the HOPE study ramipril reduced the risk of death, myocardial infarction and stroke (179). In 
the largest clinical trial investigating the effects of ACE inhibitors, the EUROPA trial, 
perindopril reduced the incidence of cardiovascular (CV) death, AMI and cardiac arrest (180). 
This effect was, however, not confirmed in the PEACE trial with trandolapril (181). No 
outcome trials have been performed in patients with UA, however, there is evidence that ACE 
inhibitors can reduce ischaemic injury also in this setting (182, 183). 
Most of the evidence regarding effects of ACE inhibitors in patients with IHD has been 
obtained in studies in patients with AMI, especially in patients with LVD. There is now 
unequivocal evidence that ACE inhibitors reduce mortality in this patient population (184-186) 
(Table 7). 
Randomized, placebo-controlled clinical trials with ACE inhibitors in heart failure patients with 
various degrees of HF severity have shown consistently a positive effect on outcome. The most 
striking effect was seen in the CONSENSUS I trial with enalapril in NYHA class IV patients, 
where mortality was reduced by 40% at 6 months (187). In the SOLVD trial, with moderate 
heart failure patients, the reduction of mortality among patients receiving enalapril was less 
marked, being 16% (188). A meta-analysis, including enalapril, captopril, ramipril, quinapril 
and lisinopril trials has confirmed the effect of ACE inhibitors in the reduction of morbidity and 
mortality in patients with heart failure (189). 
Table 7. Major clinical trials with ACE inhibitors  
Study (ref.) N Patients Drug Comparator Primary results 
SAVE (184) 2231 LVD after AMI captopril placebo all-cause mortality↓ by 19%,  
CV mortality ↓ by 37% 
AIRE (185) 2006 LVD after AMI ramipril placebo all-cause mortality ↓ by 27% 
TRACE (186) 1749 LVD after AMI trandolapril placebo all-cause mortality↓ by 22%,  
CV mortality ↓ by 25% 
EUROPA (180) 12218 Stable IHD perindopril placebo CV mortality, AMI, or  
cardiac arrest ↓ by 20% 
HOPE (179) 9297 Patients at high 
risk for CV events 
ramipril placebo AMI, stroke, or CV mortality  
↓ by 22% 
PEACE (181) 8290 Stable IHD trandolapril placebo CV mortality, AMI, or coronary 
revascularization ↓ by 4% 
CONSENSUS I 
(187) 
253 NYHA IV enalapril placebo all-cause mortality↓ by 40% 
 
SOLVD (188) 2589 NYHA II-III enalapril placebo all-cause mortality↓ by 16% 
 
About 80% of angiotensin II is generated via the ACE pathway. Since ACE inhibitors do not 
fully suppress angiotensin II production because there are other pathways through which 
angiotensin II can be produced, angiotensin II receptor blockers (ARBs) were theoretically 
thought to have great potential because of their ability to directly block angiotensin II produced 
through any pathway (190). A large body of literature has accumulated examining the effects of 
ARBs (Table 8). In placebo-controlled trials in patients with chronic heart failure they were 
superior to placebo in reducing hospitalisations and worsening heart failure, but not superior to 
placebo in all-cause mortality (191, 192). Trials comparing ARBs with ACE inhibitors have not 
revealed additional benefits of ARBs. The ELITE II study, which compared the effects of 
captopril and losartan in NYHA II-IV patients, demonstrated no statistically significant 
difference in mortality between the drugs (193). Similar results were seen in the OPTIMAAL 
and VALIANT studies with patients experiencing LVD after AMI (194, 195). Consequently, 
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ACE inhibitors have maintained their role as first choice treatment in patients with both chronic 
heart failure and AMI. ARBs have a role in patients unable to tolerate ACE inhibitors. 
Table 8. Major clinical trials with ARBs 
Study (ref.) N Patients Drug Comparator Primary results 
Val-HeFT 
(191) 
5010 NYHA II-IV valsartan placebo mortality/morbidity ↓ by 13% 
CHARM 
(192)  
7601 NYHA II-IV candesartan placebo all-cause mortality ↓ by 9% 
ELITE II 
(193) 




5477 LVD after AMI losartan captopril all-cause mortality ↑ by 13% 
VALIANT 
(195) 
14703 LVD after AMI valsartan, 
 valsartan + 
captopril 
captopril no difference in all-cause mortality 
Lipid-lowering agents 
Elevated LDL-C and triglyceride levels together with reduced HDL-C in IHD patients are well 
recognised risk factors of IHD with evidence supporting benefits of intensive LDL-C reduction 
on IHD risk (196). Currently there are five classes of drugs available for the treatment of 
dyslipidaemia: 
a) hydroxylmethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, i.e. statins  
b) fibric acid derivatives, i.e. fibrates  
c) nicotinic acid  
d) bile acid binding agents, i.e. resins, and 
e) cholesterol absorption inhibitors  
Of the above classes, statins and fibrates are widely used in clinical practice. 
Statins are the most potent LDL-C lowering agents and also the most extensively tested of the 
five classes of drugs in different clinical settings, including primary prevention. Results with 
statins show that the benefits of cholesterol lowering therapy extend into all forms of 
atherosclerotic vascular disease (197, 198). Large-scale placebo-controlled trials have been 
performed with statins in patients with history of stable angina, UA or AMI, with results 
showing that treatment with statins reduce both cardiovascular and all-cause mortality and 
incidence of major cardiovascular events, such as AMI and stroke (199-201). 
Several recent clinical trials have examined the use of statin medications early in the clinical 
course of ACS, with results showing that when the statins are used during hospital admissions 
for ACS, patients experience decreased recurrent AMI, lower death rates, and fewer repeat 
hospitalizations for ischaemia (202-204). This information suggests that all patients admitted 
for ACS should be treated with statins as drug of choice for dyslipidemias, regardless of 
cholesterol levels (Table 9). 
 23 
Table 9. Clinical trials with statins in patients with IHD 
Study (ref.) N Patients Drug Comparator Primary results 
4S (199) 4444 angina pectoris 
or AMI  
simvastatin placebo all-cause mortality↓ by 30%  
 
CARE (200) 4159 AMI  pravastatin placebo fatal coronary event or nonfatal AMI 
↓ by 24% 
LIPID (201) 9014 angina pectoris 
or AMI  
pravastatin placebo mortality due to IHD↓ by 22%  
RIKS-HIA 
(202) 
19599 AMI different 
statins 




angina or AMI 
atorvastatin placebo death, AMI, cardiac arrest or 
recurrent ischaemia ↓ by 16% 




CV death, AMI, readmission for ACS 
or stroke ↓ by 11% 
Fibrates are the second-best-studied class of lipid-lowering agents; they have reduced clinical 
events as a monotherapy. Fibrates are used in patients with low HDL-C levels, 
hypertriglyceridemia and combined hyperlipoproteinemia. By inducing the elevation of HDL-C 
levels, reduction of triglyceridemia and inflammatory state, fibrates attenuate the atherosclerotic 
burden (205). Such actions have translated into clinical benefit as demonstrated by the 
reduction in morbidity and mortality in both primary and secondary intervention trials (206-
208). 
Recently a new lipid-lowering agent, the cholesterol absorption inhibitor ezetimibe has been 
introduced (209). It has been shown to be effective in both monotherapy and especially in 
combination with statins (210, 211). In addition to potentiating the LDL-C lowering effects of 
statins and diminishing the clinical variability in response to statin therapy, the combination of 
statins and ezetimibe may produce significant additional reductions in IHD risk. 
Antiplatelet- and antithrombotic treatment 
Since coronary thrombosis is involved in both the development of atheroma and its lethal 
complications, pharmacological manipulation of the haemostatic system, with the aim of 
preventing or reducing the incidence of coronary thrombosis, is therefore of central importance 
in the treatment of patients with IHD. Several different antiplatelet and antithrombotic drugs are 
used in the IHD setting (212). 
Acetylsalicylic acid 
Acetylsalicylic acid (ASA) was introduced in the late 1890s, but only in the 1950s were its 
antithrombotic effects noted. ASA exerts its effects primarily by interfering with the 
biosynthesis of cyclic prostanoids (thromboxane A2, prostacyclin, and other prostaglandins). 
ASA irreversibly acetylates the fatty acid cyclooxygenase (COX) and inhibits the thromboxane 
A2 pathway, the latter effect mediating its antithrombotic effects. In addition, some of the 
beneficial actions of ASA in patients with coronary artery disease may be independent of its 
antithrombotic effects - these include anti-inflammatory and antioxidant properties (213). 
The best summary of the numerous trials of ASA in vascular disease have been the meta-
analyses published by the Antithrombotic Trialists’ Collaboration. One meta-analysis dealt with 
all types of antiplatelet treatments in a variety of secondary prevention trials in a wide ranging 
selection of patients at high risk for vascular events, including but not limited to unstable and 
stable angina, AMI, CABG, PTCA and heart failure. In all 195 trials, involving 135640 
patients, were identified that compared antiplatelet treatment to controls. The predominant 
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antiplatelet agent used in these trials was ASA. Overall, the allocation to antiplatelet treatment 
reduced the combined outcome of any serious vascular event by a quarter, non-fatal myocardial 
infarction by a third, non-fatal stroke by a quarter, and vascular death by a sixth, with no 
adverse effect on other deaths. The effect was similar among all forms of IHD (214). 
Heparin and warfarin 
Heparin and its derivative, low-molecular-weight heparin (LMWH, such as enoxaparin, 
fraxiparin, and dalteparin), are the anticoagulants of choice when a rapid anticoagulant effect is 
required. Heparin binds to antithrombin and this complex inactivates a number of coagulation 
enzymes, including thrombin factor (IIa), factors Xa, IXa, XIa, and XIIa (215). 
Unfractionated heparin (UFH) is not used as the sole antithrombotic drug in patients with ACS, 
rather it is combined with ASA and with thrombolytic therapy in patients with evolving AMI, 
and with GPIIb/IIIa antagonists in high-risk patients with UA or in patients undergoing high-
risk PTCA (216-220). UFH has been evaluated in a number of randomized, double-blind, 
placebo-controlled clinical trials for the short-term treatment of patients with UA or NSTEMI 
(221-224). Meta-analysis of short-term results suggests that the combination of UFH and ASA 
reduces cardiovascular death and AMI in patients with UA by about 30% over that achieved by 
ASA alone (222). Another meta-analysis found a risk reduction of 33% in cardiovascular death 
and AMI with the combination of UFH and ASA compared to placebo (218). 
LMWHs have been evaluated in numerous randomized trials in patients with UA or NSTEMI 
(225-230). A recent overview of the 6 largest trials comparing the effects of enoxaparin and 
UFH, covering 22000 patients, revealed an approximately 10-% relative reduction in risk of 
nonfatal AMI or death at 30 days of treatment with enoxaparin (231). In patients with Q-wave 
AMI, experience with LMWH is limited to studies in which most patients received 
thrombolytic therapy (232-234). The largest study enrolled 776 patients with AMI in a 
randomized, double-blind comparison of dalteparin with placebo, showing less thrombotic 
events in the dalteparin group (232). 
Oral anticoagulation with warfarin has been examined in several trials with the rationale that 
prolonged treatment might extend the benefit of early anticoagulation with either UFH or 
LMWH. Indeed, in some trials warfarin showed benefit over ASA in reduction of reinfarction 
and death (235, 236). This effect, however, has not been consistent in all trials (237). Therefore, 
currently warfarin can be considered only as an alternative to ASA in long-term antithrombotic 
treatment of patients with IHD. 
Clopidogrel 
Clopidogrel, a new antiplatelet drug, inhibits adenosine diphosphate (ADP) from binding to one 
of its three known receptors on platelets, preventing ADP mediated upregulation of the 
glycoprotein (Gp) IIb/IIIa receptor as part of the amplification phase of platelet activation. 
Several trials have evaluated the efficacy of clopidogrel in patients with IHD. The CAPRIE trial 
with 19185 patients showed that clopidogrel was slightly more effective than ASA in reducing 
ischaemic complications in patients with atherosclerotic vascular disease (238). The CURE trial 
with 12 562 patients presenting with non-ST elevation ACS showed that combining clopidogrel 
with ASA leads to a further reduction in cardiovascular death, non-fatal AMI, and stroke (239). 
The PCI-CURE, a prospective observational study in 2658 patients enrolled in the CURE study 
who underwent a percutaneous coronary intervention (PCI) in response to refractory symptoms 
or adverse events, showed that clopidogrel was effective also as a pre-treatment before PCI, 
reducing the incidence of AMI and ischaemia (240). 
 25 
Glycoprotein IIb/IIIa inhibitors 
Activation of the glycoprotein (Gp) IIb/IIIa receptor on platelets is the final common pathway 
leading to platelet aggregation, intracoronary thrombus formation, and myocardial ischaemia. 
Several randomized controlled trials have examined the effect of four different intravenous Gp 
IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide and lamifiban) in patients presenting with 
non-ST elevation ACS. There was, however, pronounced heterogeneity in the outcomes of these 
trials. The CAPTURE, PRISM PLUS and PURSUIT trials with 1265, 1915 and 10948 patients, 
respectively, showed a significant reduction in their primary endpoints at 30 days (216, 217, 
241). In contrast, the PRISM, PARAGON and GUSTO IV trials with 3232, 2282 and 7800 
patients, respectively, failed to show a significant difference in their primary endpoints at 30 
days (242-244). The treatment effect of these agents appears to be greatest among those patients 
with elevation of troponin and those undergoing early PCI. The apparent divergence in efficacy 
among the various Gp IIb/IIIa inhibitors in the cardiac catheterisation laboratory and in ACS 
may be explained by differences in the level and duration of platelet inhibition achieved by the 
various regimens used in these different settings. 
No reduction in ischaemic events with oral Gp IIb/IIIa antagonists has been demonstrated, 
despite clinical trial experience with over 40 000 patients and the study of four different oral Gp 
IIb/IIIa antagonists (orbofiban, sibrafiban, xemilofiban and lotrafiban) (245-248). Of greater 
concern is the emerging evidence suggesting an increase in mortality with these agents (249). 
The reason for this finding remains to be clarified, although there are data suggesting that Gp 
IIb/IIIa inhibitors may have a prothrombotic or proinflammatory effect (250, 251). 
Furthermore, there may be genetic differences between patients in their response to these agents 
(252). 
Hirudin and bivalirudin 
Hirudin and bivalirudin, known as direct thrombin inhibitors (DTIs), interact directly with 
thrombin and inactivate fluid-phase and bound forms of the enzyme. Since DTIs do not bind to 
plasma or tissue proteins, their anticoagulant effect is considered more predictable (253). Given 
the promising pharmacologic characteristics of DTIs, there have been a number of clinical trials 
that have investigated the role of these agents. In one meta-analysis of 11 randomized trials of 
DTIs versus UFH, in 35970 patients with STEMI, non ST-elevation acute coronary syndrome 
(NSTE ACS), or undergoing PTCA, DTIs were associated with a significantly lower risk of 
death or AMI at 30 days (254). 
Multiple clinical trials have compared DTIs with UFH in patients undergoing PTCA. In the 
HELVETICA trial hirudin was associated with a significant reduction in early death, AMI, and 
urgent revascularization within 96 hours of PTCA, but a higher incidence of bleeding was seen 
with hirudin (255). The Bivalirudin Angioplasty Trial randomized 4098 patients undergoing 
PTCA for NSTE ACS or postinfarction angina to UFH or bivalirudin immediately before 
angioplasty. Bivalirudin was not significantly different from UFH in reduction of the incidence 
of in-hospital death, AMI, abrupt vessel closure, or cardiac deterioration necessitating PTCA 
(256). In the largest of the trials comparing DTIs with UFH, the HERO-2 trial in 17073 patients 
with STEMI, bivalirudin did not reduce mortality compared with UFH, but did reduce the rate 
of reinfarction within 96 h by 30% (257). 
Fibrinolytic therapy and revascularisation procedures 
Pharmacological reperfusion therapy for AMI was incorporated into the armamentarium of 
physicians in the 1980s and has had an extraordinarily beneficial impact on the outcome of 
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STEMI patients. The treatment is more efficient when administered between 0 and 6 h (30 
deaths prevented per 1000 treated) than between 7 and 12 h (20 deaths prevented per 1000 
treated). This underscores that the time window for effective treatment is limited as thrombi 
will grow and consolidate with time and increase the extent of irrevocable muscle necrosis 
(258). 
Numerous large trials have verified the efficacy of different fibrinolytics in reduction of 
mortality and morbidity in STEMI patients (Table 10). In the first major study on fibrinolytics, 
the GISSI-1 study, streptokinase reduced total mortality by 19% compared with standard 
therapy (259). In the ISIS-2 study additional benefit was obtained by concomitant 
administration of ASA (260). The GISSI-2 and ISIS-3 studies evaluated the efficacy of 
alteplase, a recombinant tissue plasminogen activator (rt-PA), a drug capable of degrading 
fibrin of the thrombus more selectively than streptokinase. No specific differences regarding 
clinical endpoints were seen in either study in comparison with streptokinase (261, 262). In the 
GUSTO I trial alteplase combined with UFH provided a 14-% benefit over streptokinase 
combined with UFH, but an increased frequency of haemorrhagic strokes was seen with 
alteplase (263). The GUSTO III and ASSENT-2 trials with reteplase and tenecteplase, 
respectively, did not provide any additional survival benefit over alteplase (264, 265). 
Table 10. Major clinical trials with fibrinolytics in STEMI patients  
Study (ref.) N Drug Comparator Primary Result 
GISSI-1 
 (259) 
11712 streptokinase - in-hospital mortality ↓ by 19% 
GISSI-2 
(261) 
12490 alteplase streptokinase no difference between treatments regarding death 
and severe LV damage 
ISIS-2 
(260) 
17817 streptokinase ASA, 
placebo 
5-week vascular mortality ↓ by 25% after 
streptokinase, ↓ by 42% after streptokinase+ASA 
ISIS-3 
(262) 
41299 streptokinase duteplase no difference between treatments 
 in 5-week mortality 
GUSTO-1 
 (263) 




15059 reteplase alteplase  no difference between treatments 
 in 30-day mortality 
ASSENT-2 
(265) 
16949 tenecteplase alteplase no difference between treatments 
 in 30-day mortality 
Revascularisation procedures, i.e. PCI (PTCA and stenting) and CABG, are now widely utilized 
in the treatment of IHD. A trial in stable angina, RITA-2 in 1018 patients, comparing efficacy 
of PTCA and medical therapy, showed that early intervention with PTCA was associated with 
greater symptomatic improvement, especially in patients with more severe angina (266). In 
long-term follow-up it was seen that an initial strategy of PTCA did not influence the risk of 
death or MI, but improved angina and exercise tolerance (267). In UA, the use of PTCA has 
been associated with an increased risk of AMI, need for emergency surgery and restenosis, 
compared with CABG (268). The introduction of intracoronary stents, both bare and drug-
eluted stents together with new antiplatelet agents such as clopidogrel and glycoprotein IIb/IIIa 
inhibitors, have improved both short- and long-term outcomes in this patient population (269-
273). 
The success of PCI in the treatment of STEMI is highly dependent on timing. PCI is the 
preferred therapeutic option when it can be performed within 90 min of the first medical contact 
(so-called primary PCI). For several years primary PCI has been applied as an alternative to 
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fibrinolytic therapy. Several trials have been performed in order to compare the efficacy of 
primary PCI with that of fibrinolysis. Results have shown effective restoration of patency, less 
reocclusion, improved ventricular function and clinical outcome after PCI (274-279). The 
superiority of PTCA over fibrinolysis has also been seen in meta-analyses (280, 281). However, 
as time to reperfusion is critical, thrombolysis remains a valuable option for many patients with 
STEMI. The value of pre-hospital thrombolysis was evaluated in the CAPTIM study with 840 
patients, where the outcomes of fibrinolysis were not different from those seen with PTCA 
(282). Due to the potential thrombotic reaction connected to primary PCI, pretreatment with 
thrombolytics, Gp IIb/IIIa inhibitors or both has been introduced in order to favourably 
influence the incidence of reinfarction and death (283-286). Primary PCI improved prognosis 
also in patients with cardiogenic shock (287, 288). 
In summary, revascularisation procedures – CABG or PCI – have proved to be efficacious and 
shown to improve prognosis in many different patient populations. The decision regarding the 
specific procedure to be used is based on the number of involved vessels, comorbidities, degree 
of left ventricular dysfunction and also on how experienced the medical personnel is. 
2.4.2 Symptomatic therapy 
Nitrates 
The clinical effects of nitrates were first described in the 19th century. Organic nitrates are 
prodrugs and must be biodegraded to have therapeutic effects. This biotransformation involves 
denitration of the nitrate, with the subsequent liberation of nitric oxide. Nitric oxide stimulates 
guanylyl cyclase, which reduces cytoplasmic calcium by inhibiting calcium inflow and by 
stimulating mitochondrial uptake of calcium. This leads to the conversion of guanosine 
triphosphate to cyclic guanosine monophosphate, which in turn causes vasodilation. The effects 
are seen in both coronary arteries and veins, resulting in reduction of preload and afterload. 
Therefore, nitrates are considered useful in the treatment of IHD and also heart failure (289, 
290). 
The most conventional and often used nitrate formulation is sublingual nitroglycerin, which is 
the drug of choice for the treatment of angina episodes in both stable and unstable form of 
angina and for the prevention of angina (289-291). Other preparations, such as oral isosorbide 
dinitrate, isosorbide 5-mononitrate as well as intravenous nitroglycerin, nitroglycerin ointment 
and transdermal patches are used in order to prolong the action of the drug and obtain more 
stable and longer-lasting clinical effects than seen with those after administration of sublingual 
nitroglycerin. 
The major problem with the use of nitrates is the development of tolerance, which has been 
demonstrated to occur with all forms of nitrates (289, 290). The most widely accepted 
explanation to this is depletion of sulfhydryl groups, which are the crucial component of 
metabolic conversion of nitroglycerin to nitric oxide. The only practical strategy in tolerance 
management is to provide a nitrate-free interval. Also rebound effect after withdrawal of 
therapy has been observed, which requires that the withdrawal of nitrate therapy be done 
carefully (292). 
Despite nitrates having been in clinical use for a long time, there is no long-term clinical trial 
evidence about their effects in patients with angina. Nitrates did not influence morbidity or 
mortality in patients with AMI in two large-scale clinical trials, GISSI-3 and ISIS-4 (293, 294). 
In patients with heart failure, in contrast, the combination of isosorbide dinitrate and the 
vasodilator-drug hydralazine did improve haemodynamics and decrease mortality (295, 296). In 
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patients with acute heart failure intravenous nitroglycerin and nitroprusside are widely accepted 
as first-line therapy, although prospective studies regarding their effect on prognosis have not 
been performed (297, 298). Thus, the use of nitrates in the treatment of IHD is largely based on 
pathophysiological considerations and clinical experience rather than evidence from 
randomized clinical trials. 
Calcium antagonists 
Calcium antagonists, introduced in clinical medicine in the 1960s, are a heterogenous group of 
compounds inhibiting calcium ion movement through channels in cardiac and smooth muscle 
membranes by blockade of voltage-sensitive L-type calcium channels. The efficacy of calcium 
antagonists in treatment of IHD is related to their ability to reduce myocardial oxygen demand 
and increase oxygen supply. They cause relaxation of vascular smooth muscle in both systemic 
arterial and coronary arterial beds. The blockade of the entry of calcium into myocytes results 
also in a negative inotropic effect. There are three major classes of calcium antagonists 
currently in clinical use: dihydropyridine-type (such as nifedipine, felodipine, amlodipine, 
lacidipine), phenylalkylamines (such as verapamil, gallopamil) and benzothiazepines (such as 
diltiazem) (299, 300). 
Dihydropyridine-type calcium antagonists 
Dihydropyridine-type calcium antagonists are particularly effective in dilation of vascular 
smooth muscle. Negative inotropic, chronotropic, and dromotropic effects are rather small. In 
rare instances they can lower blood pressure excessively with subsequent reflex tachycardia. 
Second-generation dihydropyridine-type calcium antagonists, such as amlodipine, felodipine 
and lacidipine are more vascular selective than calcium-antagonists of the first generation 
(nifedipine) (299, 300). Dihydropyridine-type calcium antagonists and their combination with 
beta-blockers have been shown to be efficacious in the treatment of stable angina pectoris and 
also in Prinzmetal (variant) angina (301-305). 
The short-acting formulation of nifedipine has been studied mostly in patients with AMI and 
UA. Several early trials have shown that nifedipine increases mortality in this patient 
population (162, 306-308). A meta-analysis of 16 trials of short-acting nifedipine in patients 
both during and after myocardial infarction or with UA confirmed the existence of such an 
effect (309). The question remains whether this finding is relevant only to short-acting 
nifedipine, since there are very limited data on either long-acting nifedipine or the other 
dihydropyridines (such as felodipine or amlodipine) in this indication. 
Second-generation dihydropyridine-type calcium antagonists have been evaluated in several 
clinical trials in patients with heart failure, however, without substantial efficacy. In the V-
HeFT III trial, where felodipine was tested as a supplementary drug to enalapril, felodipine did 
not improve exercise tolerance, quality of life, or reduce hospitalizations or mortality (310). The 
finding was similar in the PRAISE trial with amlodipine (311). However, no harm has been 
observed with long-term treatment, which indicates that these drugs may be safely used in 
patients experiencing angina together with left ventricular dysfunction (312). 
Recently some new evidence about the antioxidant properties of calcium antagonists has been 
presented indicating that these drugs can reduce the rate of progression of atherosclerosis (313-
315). In the REGRESS study, co-administration of amlodipine or nifedipine with pravastatin 
caused a significant reduction in the appearance of new angiographic lesions (316). Recent 
results of the ELSA study show that lacidipine reduced the progression rate of intima-media 
thickening as compared to atenolol (317). 
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Phenylalkylamine-type calcium antagonists 
Verapamil, the most often used phenylalkylamine-type calcium antagonist, dilates peripheral 
and coronary vessels, slows heart rate and has a marked negative inotropic effect. This results 
in a reduction in myocardial oxygen requirement, which makes verapamil a suitable treatment 
for different forms of IHD. Verapamil has been shown to be useful in the treatment of chronic 
stable angina, its efficacy being similar to that seen with beta-blockers (318-320). The INVEST 
study showed that a verapamil-trandolapril-based strategy was clinically as effective as an 
atenolol-hydrochlorothiazide-based strategy in hypertensive IHD patients (321). In the DAVIT 
II trial verapamil reduced the incidence of recurrent myocardial infarction and death (322) and a 
similar result has been seen in one meta-analysis (323). Verapamil is also useful in the 
treatment of variant angina (324). 
Benzothiazepine-type calcium antagonists 
Diltiazem, the most commonly used phenylalkylamine-type calcium antagonist, possesses 
vasodilator effects that are intermediate between those of dihydropyridine-type calcium 
antagonists and verapamil. Its vasodilator effects are less profound than those of 
dihydropyridines and its negative ino-and dromotropic effects smaller than those of verapamil. 
Diltiazem has been shown to be effective in the treatment of stable angina and its efficacy was 
better compared with other calcium antagonists (302, 325, 326). In patients with UA diltiazem 
has been more effective than nitrates in both short and long term and similar in efficacy to beta-
blockers (327-330). Diltiazem has been found useful in the treatment of variant angina (324). In 
patients with AMI, diltiazem has improved left ventricular systolic function (331) and reduced 
the need of myocardial revascularization after thrombolysis (332). However, in the large-scale 
MDPIT study diltiazem had no effect on long-term prognosis (333). 
In summary, calcium antagonists are effective in the treatment of stable angina and can be used 
in patients with UA or AMI in case of recurrent ischaemia despite beta-blockade (or in whom 
beta-blockers are contraindicated). Calcium antagonists are not recommended in patients with 
heart failure. 
Other vasodilators 
Several vasodilating drugs have been evaluated in treatment of IHD. One of the most 
extensively studied vasodilators is nicorandil, a drug with both nitrate-like and K+ATP channel 
opening properties (334). By virtue of this dual mechanism of action, the drug acts as a 
balanced coronary and peripheral vasodilator and reduces both preload and afterload (334). 
Nicorandil has been shown to induce ischaemic preconditioning in several animal and clinical 
studies (103, 335, 336). Studies in animal models of ischaemia-reperfusion-induced myocardial 
stunning or infarction indicate that nicorandil has cardioprotective effects (337-341). Various in 
vitro and animal studies have shown that the cardioprotective mechanism of nicorandil includes 
inhibition of oxidative stress-induced apoptosis of cardiac myocytes during reperfusion (342-
344) and preservation of mitochondrial respiration and ATP production during reoxygenation 
(345, 346). 
The efficacy of nicorandil has been evaluated in several clinical trials. The largest of these, the 
IONA study, was performed in 5126 patients with stable angina and showed reduction in major 
coronary events among patients receiving nicorandil (347). In the placebo-controlled CESAR 2 
trial in patients with UA nicorandil reduced the incidence of myocardial ischaemia and had 
some antiarrhythmic effect (348). Nicorandil has also improved exercise capacity in patients 
with stable angina and the effect was comparable with those of nitrates, beta-blockers and 
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calcium antagonists (349-354). Studies in patients undergoing PTCA have shown that the 
administration of nicorandil enhances myocardial tolerance to ischaemia both in patients with 
angina and in patients with AMI (335, 355, 356). In patients with heart failure the effects of 
nicorandil were similar to those of nitroglycerin, however, less tachyphylaxis was seen in 
patients receiving nicorandil (357). 
Molsidomine, a sydnonimine, resembles nitroglycerin in its mode of action. It has been studied 
mostly in patients with stable angina, in whom it was rather effective (358, 359). In patients 
with AMI, however, it has no favorable effects on either short- or long-term prognosis (360). 
Molsidomine has been studied also in patients with heart failure, but the data is very limited 
(361). 
2.5 Positive inotropic drugs in the treatment of ischaemic heart failure 
Positive inotropic drugs represent one of the oldest classes of drugs, used for treatment of both 
chronic and acute heart failure. During past decades new inotropic drugs have been synthesized 
and relatively thoroughly examined in different clinical settings. 
Digitalis 
Digitalis, the extract of the common foxglove plant Digitalis purpurea, has been used for 
treatment of edematous states, irregular heartbeats, and CHF for centuries. Digoxin’s primary 
mechanism of action is the ability to inhibit membrane-bound alpha subunits of sodium-
potassium ATPase (sodium pump), mainly located in the human myocardium. This inhibition 
promotes sodium-calcium exchange, which increases the concentration of intracellular calcium 
that is available to contractile proteins, resulting in an increase in the force of myocardial 
contraction (362-364). The beneficial effects of digoxin on HF may be related in part to its 
modulating effects on neurohormonal abnormalities, such as attenuation of carotid sinus 
baroreceptor discharge sensitivity, vagomimetic and sympathoinhibitory effects (365-368). 
Several small and medium-size clinical trials have been performed with digoxin in heart failure. 
In the PROVED and RADIANCE studies, digoxin withdrawal in patients with systolic 
dysfunction was associated with a decrease in LVEF, renal function, exercise tolerance and 
quality of life and an increase in the incidence of worsening heart failure (369, 370). The largest 
trial with digoxin, the DIG trial, assessed all-cause mortality in 6800 patients with NYHA I-IV 
HF and decreased systolic function, with the patients receiving diuretics and ACE inhibitors. In 
this trial, digoxin had neutral effects on mortality, but hospitalizations related to worsening HF 
were significantly reduced. The effect was more pronounced in severe heart failure patients 
(371). 
Phosphodiesterase inhibitors 
Phosphodiesterase (PDE) III inhibiting drugs (such as amrinone, milrinone and enoximone) 
increase contractility by reducing the degradation of cyclic adenosine monophosphate (cAMP). 
In addition, they reduce both preload and afterload via vasodilation. The haemodynamic 
consequences of this action are reduced left ventricular afterload, increased cardiac output (CO) 
and reduced total peripheral resistance. Unlike sympathomimetic amines, PDE III inhibitors 
produce no tolerance and possess the distinct advantage of directly decreasing pulmonary 
vascular resistance (372-375). 
Milrinone is the most widely used PDE III inhibitor. Two large prospective randomized studies 
have been conducted with milrinone, one with an oral and the other with an intravenous 
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formulation. The PROMISE study evaluated the efficacy of oral milrinone in 1088 patients with 
NYHA class III or IV congestive heart failure. As compared with placebo, milrinone was 
associated with a 28-% increase of all cause mortality (376). In the OPTIME-CHF trial 951 
patients with decompensated heart failure were randomized to either intravenous milrinone or 
placebo. The study failed to show any benefits of milrinone over placebo in morbidity and 
mortality and milrinone was associated with a higher incidence of adverse events (377). 
While amrinone has been largely abandoned as treatment of heart failure, mainly due to its 
ability to cause thrombocytopenia, low-dose oral enoximone has recently been evaluated in 
several small clinical trials, especially its effects during co-administration with beta-blockers 
(378-380). 
Another drug, vesnarinone, a mixed PDE inhibitor and ion-channel modifier that has modest, 
dose-dependent, positive inotropic activity, but minimal negative chronotropic activity, has 
improved haemodynamics and quality of life in small trials (381-383). However, in the largest 
outcome study, the VEST trial with 3833 patients with severe heart failure, a dose-dependent 
increase in mortality was identified (384). 
Dobutamine and dopamine 
Dobutamine, a beta-adrenoreceptor agonist improves haemodynamics in patients with heart 
failure after cardiac surgery and AMI, both as long-term infusion and also in the outpatient 
setting (11-13, 93, 385-390). In several small trials the administration of dobutamine was 
associated with an increased risk of mortality, which may be due to dobutamine’s chronotropic, 
proischaemic and proarrhythmic effects (391-393). Also, in the yet unpublished CASINO trial 
an adverse effect of dobutamine on survival was seen; however, the sample size of the trial – 
299 patients – was again too small to provide conclusive evidence (394). 
Dopamine is an endogenous catecholamine that is precursor to norepinephrine in the 
catecholamine synthetic pathway. At lower doses dopamine causes vasodilation of splanchic 
and renal arterial beds, whereas at higher doses peripheral vasoconstriction occurs as a result of 
alpha-adrenergic receptor stimulation (375, 395). Therefore, dopamine has been used in low 
doses to support renal perfusion (396-398). Nevertheless, sufficient evidence is still lacking on 
reduction in endpoints such as mortality or renal replacement therapy. In addition, several 
studies have failed to find expected specific renal effects of dopamine (399, 400). In 
conclusion, well-controlled clinical trials remain mandatory to assess the overall clinical effects 
of dopamine in treatment of both renal and heart failure. 
Calcium sensitizers 
These positive inotropic agents act by increasing the sensitivity of troponin C or some other 
part of the myofibrillar Ca2+ – binding apparatus to ionized calcium. There are several drugs 
with reported calcium sensitizing properties (sulmazole, isomazole, adibendan, meribendan, 
EMD 53998, DPI 201-106, Org 30029, APP 201-533, and MCI-154), but most of the clinical 
data come from two compounds: pimobendan and levosimendan. 
Pimobendan is a calcium sensitizer with PDE III inhibitor properties, currently available for 
treatment of heart failure only in Japan. Both intravenous and oral formulations have been 
studied in patients with heart failure. Intravenous bolus doses had clear inotropic, vasodilatory 
and chronotropic effects in patients with heart failure, increasing CO and reducing systemic 
vascular resistance and left ventricular end-diastolic pressure (401, 402). In comparison with 
captopril, pimobendan appeared to be a stronger arterio-venodilator (403). 
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The effects of oral pimobendan were similar to those seen after intravenous administration 
(404-407). Several trials have evaluated long-term efficacy of pimobendan also during chronic 
oral administration. In those trials pimobendan increased exercise duration, peak oxygen uptake 
and improved quality of life (405, 408-411). The efficacy and safety were similar to those seen 
with enalapril, although a somewhat higher incidence of arrhythmias was seen in Holter-
recordings (412, 413). 
However, in the PICO trial with 317 patients with stable symptomatic heart failure and LVEF 
less than 45%, although pimobendan improved exercise duration, a trend towards increased 
mortality was seen in the pimobendan group and this effect was more pronounced among 
patients receiving concomitant digoxin (414). In contrast, the most recent placebo-controlled, 
double-blind study with pimobendan, the EPOCH study in 306 patients found that pimobendan 
significantly lowered morbidity and improved the physical activity of patients with stable 
NYHA II-III heart failure without increase in adverse cardiac events (415). Therefore, the role 
of pimobendan in the treatment of heart failure remains to be clarified and adequately powered 
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Figure 1. Structural formula of levosimendan. 
2.6.2 Mechanism of action 
Levosimendan exerts its effects mainly through two different mechanisms: positive inotropic 
effect, obtained by calcium sensitisation of the contractile proteins in cardiac muscle, and 
vasodilation, caused by opening the ATP-sensitive potassium channels in both vascular and 
cardiac tissue. 
Positive inotropic effect 
Levosimendan induces inotropy through the calcium-dependent binding of the drug to the 
calcium-saturated N-terminal domain of cardiac troponin C, which stabilises and prolongs the 
life span of the molecule (Figure 2) (14, 15, 416). Since levosimendan dissociates from cardiac 
troponin C at low calcium concentration (15), it does not impair relaxation (16, 417). 
Levosimendan has been shown to increase calcium sensitivity of contractile proteins in intact 
cells without altering the calcium content of sarcoplasmatic reticulum (17). The positive 
inotropic effect of levosimendan has been demonstrated by experiments in isolated 
cardiomyocytes (17), papillary muscles (16, 418), ventricular muscle strips (419) and in 











Figure 2. Calcium sensitisation of the contractile proteins in cardiac muscle by levosimendan. 
Vasodilation 
The second mechanism – vasodilation – is due to the opening of ATP-sensitive K-channels 
(K+ATP channels). This effect has been electrophysiologically demonstrated in arterial and 
venous preparations and in coronary arteries (19, 422). The vasodilator effects on human 
coronary conductance and resistance arteries have been demonstrated also in patients (423). It 
has also been shown that the venodilatory effect of levosimendan on the noradrenaline-
constricted human saphenous vein is mediated by the opening of K+ATP channels (424). In 
addition, some pharmacological findings indicate that the compound may open the voltage-
dependent potassium channels in coronary arteries (425). 
Anti-ischaemic effect 
In a dog infarction model, levosimendan – given before ischaemia - reduced infarct size by 
50%. This reduction of infarct size was abolished by the K+ATP channel blocker glibenclamide. 
This proves that levosimendan has an anti-ischaemic effect, which is mediated via opening of 
K+ATP channels (20). Levosimendan opens the K+ATP channels also in rat ventricular myocytes 
(18). This effect, however, does not produce negative inotropy as it does in the case of all other 
potassium channel openers. In conclusion, the anti-ischaemic effect of levosimendan is 
mediated via opening of K+ATP channels. Levosimendan opened the K+ATP channels also in rat 
liver mitochondria, in a manner dependent on the potassium concentration (426). The effect 
was abolished by 5-hydroxydecanoate, a selective blocker of mitochondrial K+ATP channels. 
The effect of oral administration of racemic simendan on the survival of rats with healed AMI 
after coronary ligation has been studied. The material was divided into control and 3 treatment 
groups receiving simendan, milrinone or enalapril. After a follow-up period of 312 days the 
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infarct size-corrected mortality in control, simendan, enalapril and milrinone groups was 76%, 
53%, 62% and 70%, respectively (427). 
PDE inhibition 
Intracellular calcium levels are not affected by levosimendan at therapeutically relevant 
concentrations, but several studies have shown that levosimendan also inhibits highly 
selectively phosphodiesterase type III activity and causes accumulation of cyclic adenosine 
monophosphate with resultant increased influx of calcium into the myocyte (419, 428-430). 
However, this effect was associated only with higher levosimendan concentrations and 
therefore probably does not contribute significantly to the contractility-enhancing and 
vasodilatory effects of levosimendan at therapeutic concentrations (21, 418). 
2.6.3 Pharmacokinetics and metabolism 
The terminal elimination half-life (t1/2el) of levosimendan is about 1 hour (431-433). 
Levosimendan is highly bound to plasma proteins (97-98%) (431, 434). During intravenous 
administration the concentrations of levosimendan increase dose proportionally (435). The 
bioavailability of levosimendan from an oral solution is approximately 80% and it is rapidly 
absorbed reaching peak concentrations within 1 to 2 hours after an oral capsule (431). 
Levosimendan is metabolised through glutathione conjugation at one of its nitrile groups and 
through subsequent amino acid cleavage and cyclication or acetylation. The main pathway is 
conjugation with glutathione to inactive metabolites and the minor pathway (only 
approximately 5% of the total levosimendan dose) is reduction in the intestine to the 
aminophenylpyridazinone metabolite OR-1855. The amine metabolite is further metabolized by 
acetylation to the N-acetylated conjugate OR-1896 (436). The enzyme responsible for the 
acetylation of OR-1855 to OR-1896 is suspected to be N-acetyltransferase and as this enzyme is 
polymorphically distributed in the population, the acetylation capacity of the individual 
determines the plasma levels of OR-1896 during treatment with levosimendan (437). Also an 
inactive hydration product, OR-1420, is formed through addition of water to one of the nitrile 
groups. Levosimendan is excreted via urine and faeces as conjugates and only traces of 
unchanged levosimendan are found in urine or faeces in experimental animals and in man (431, 
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Figure 3. The metabolic pathways of levosimendan 
The metabolite OR-1896 has been shown to have haemodynamic properties similar to those of 
the parent drug (439-441). In different experimental animals, the elimination half-life of 
levosimendan was 0.25 to 1.3 hours, whereas that of the metabolite OR-1896 was 4.7 to 6.5 
hours (436). In humans, the mean elimination half-life values for the levosimendan metabolites 
OR-1855 and OR-1896 are approximately 80 hours (442, 443). The mean plasma protein 
binding values are 39% for OR-1855 and 42% for OR-1896 (444). 
Several interaction studies have been performed with levosimendan. No pharmacodynamic or 
pharmacokinetic interactions have been seen with captopril, itraconazole, warfarin, isosorbide 
5-mononitrate or carvedilol (434, 445-448). 
2.6.4 Clinical experience with levosimendan 
Studies in healthy volunteers 
In studies with healthy volunteers, levosimendan has been shown to increase CO and ejection 
fraction dose-dependently (435). The increase in CO at low doses was due exclusively to an 
increase in stroke volume. No increases in heart rate have been seen with doses of up to 1 mg of 
intravenous levosimendan (433, 435, 449). 
The enhancement in cardiac performance was attributed both to an increase in contractility, 
assessed by systolic time intervals (433, 447, 449) and echocardiography (435), and to a 
reduction in afterload, reflected by a dose-dependent decrease in systemic vascular resistance 
(433, 435, 449). Levosimendan increased leg blood flow with only minor increases in skin 
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blood flow, indicating that the increased flow was directed predominantly to the skeletal 
muscles (447). The effects of levosimendan on cardiac performance were maintained during 
light dynamic exercise (449). Systolic BP generally increased or was unchanged, and dBP has 
consistently been shown to decrease (433, 435, 449). The haemodynamic efficacy of 
levosimendan was not associated with a significant increase in myocardial oxygen 
consumption. In a study, utilising positron emission tomography with 11C-acetate, 
levosimendan, in comparison with placebo, increased myocardial oxygen consumption non-
significantly (+12%), whereas dobutamine increased oxygen consumption markedly (+58%) 
(22). 
Studies in patients 
Designs of main studies 
Intravenous levosimendan has been studied by now in more than 3000 patients and several 
medium and large-scale studies have been carried out. Mostly these studies have been carried 
out in patients with chronic heart failure. The presence of patients with acute or chronic IHD 
varies between the studies. The main levosimendan studies and doses used in them are 
summarised in Table 11. 
The therapeutic dose range of levosimendan administered over a 24-hour period was studied in 
a placebo-controlled, double-blind, parallel-group, randomized study including 151 patients 
with stable (mainly NYHA class III) heart failure of ischaemic origin, but patients with recent 
AMI (within 3 months before enrollment) were excluded (450). 
Forced up-titration, maintenance and withdrawal of levosimendan was studied in a placebo-
controlled, double-blind, parallel-group, randomized study in 146 patients hospitalized for 
decompensated heart failure (NYHA class III or IV) due to IHD or dilated cardiomyopathy. 
Patients with significant IHD (angina-limited exercise, unstable angina or AMI within 8 weeks) 
were excluded. The study was divided into three phases. During the first 6-hours, escalated 
doses of levosimendan (n=98) were compared to placebo (n=48). From 6 to 24 hours, the 
patients in the levosimendan group continued to receive the drug as an open-label infusion. At 
24 hours, the remaining patients were randomized to continue on levosimendan (levosimendan 
continuation group) or placebo (levosimendan withdrawal group) in a double-blind fashion up 
to 48 hours (451, 452). 
The haemodynamic efficacy (increase in cardiac index and decrease of PCWP) of 24-hour 
levosimendan infusion was compared to dobutamine in a double-blind, parallel-group, 
randomized trial in 203 patients with low-output heart failure in need of intravenous inotropic 
support (the LIDO study). Patients had either an ischaemic or non-ischaemic etiology of heart 
failure, however, patients with acute ischaemia were excluded also from this study (453). 
The efficacy of 24-hour levosimendan infusion was compared to dobutamine and placebo in a 
double-blind, parallel-group, randomized trial in 299 patients with severe (NYHA IV) heart 
failure (the CASINO study). Patients with both ischaemic or non-ischaemic etiology of heart 
failure were studied (394). 
The on-going REVIVE study evaluates the efficacy of 24-hour levosimendan infusion on 
symptoms of heart failure with a new composite endpoint, consisting of patient’s subjective 
symptom assessment and signs of worsening symptoms (including death) during five days after 
starting a 24-hour study drug infusion. The study is a placebo-controlled, double-blind, parallel-
group, randomized trial in patients with acutely decompensated heart failure. Patients with 
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either ischaemic or non-ischaemic etiology of heart failure are studied, however, patients with 
acute ischaemia (within 6 hours) are excluded. The pilot phase of this study (REVIVE I) has 
been published recently with preliminary data on 100 subjects (454). 
Another on-going, double-blind, parallel-group, randomized trial, the SURVIVE study, 
evaluates the effect of 24-hour levosimendan infusion on survival in comparison with 
dobutamine in patients with decompensated heart failure and in need of intravenous inotropic 
support. Patients with ischaemic (including AMI) or non-ischaemic etiology of heart failure are 
studied. In addition, the study includes the option of re-administration of study drugs, a feature 
that has not been implemented in any previous trials with intravenous levosimendan (455). 
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Mortality 
N= number of patients 
LS = number of levosimendan patients 
*) a 10-min loading dose of 3-36 µg/kg preceded the maintenance infusions 
**) consisting of two separate studies: REVIVE I as a pilot phase and REVIVE II - a large phase III study 
***) dobutamine dose at least 5 µg/kg/min and duration at least 24 h, otherwise unlimited. 
Results 
Haemodynamics 
Levosimendan exerted significant, dose-dependent increases in CO, stroke volume and heart 
rate, and decreases in PCWP, mean blood pressure, mean pulmonary artery pressure, mean 
right atrial pressure and total peripheral resistance (Figure 4) (450). The effect of levosimendan 
on haemodynamic variables (CO, stroke volume, heart rate, and PCWP) was clearly evident 
already at the end of a 5-minute bolus infusion (456). There is no sign of development of 
tolerance with a prolonged infusion up to 48 hours (Figure 5) (451, 452). Compared to 
dobutamine, levosimendan produces a similar increase in CO, but profoundly greater decrease 
in PCWP (453). In contrast to the haemodynamic effects of dobutamine, those of levosimendan 
are not attenuated by concomitant beta-blocker use (453). Due to the formation of the active 
metabolite OR-1896, the haemodynamic effects are maintained several days after stopping 
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Figure 4. Change in CO and PCWP at 24 hours compared with baseline after a 24-hour 
infusion of 5 doses of levosimendan, placebo (PBO), or dobutamine (DOB, dose 6 
µg/kg/min) in 151 patients with stable heart failure. Mean (± SEM) values are 
shown. P<0.001 for linear dose trend (450). 





























































































Figure 5. Mean (± SEM) changes in stroke volume (A), PCWP (B) and plasma concentration-
time curves of levosimendan (C) and the metabolite OR-1896 (D) (452). 
The beneficial effects of levosimendan on haemodynamics are not associated with an increase 
in myocardial energy consumption. This was evidenced by utilizing dynamic PET technique in 
8 hospitalized patients with heart failure (NYHA III-IV) (23). The patients were given 
levosimendan 18 µg/kg as a loading dose followed by a continuous infusion of 0.3 µg/kg/min 
for about 5 hours, and placebo in a cross-over fashion. Despite increases in both CO and stroke 
volume, myocardial oxygen consumption was unaltered by levosimendan. 
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Symptoms 
The effects of levosimendan on dyspnoea and fatigue have been evaluated in several trials. In 
the dose-escalation/withdrawal study dyspnoea improved in statistically significantly more 
patients treated with levosimendan (29%) than in patients receiving placebo (15%) at 6 hours 
after starting the treatment (p=0.037). There was a trend toward improvement also in fatigue 
with more patients in the levosimendan group reporting improvement (42% versus 22%, 
p=0.057) (451). 
In the LIDO study, symptoms improved equally well in levosimendan- and dobutamine-treated 
patients at 24 hours. Dyspnoea improved in 68% and 59% (p=0.865) of the patients in the 
levosimendan and dobutamine groups, respectively. Fatigue improved in 63% and 47% 
(p=0.155) of patients with levosimendan and dobutamine, respectively (453). 
In a pilot phase of the REVIVE study (REVIVE I), improvement was observed more frequently 
in levosimendan-treated patients than in patients on placebo (49% vs 33%), although the 
difference was not significant (p=0.229), most probably due to the small number of patients 
included, 100. The greater level of improvement in the clinical composite on levosimendan was 
supported by significant reductions in plasma BNP concentrations compared to placebo at both 
24 hours and 5 days (p<0.05) (454).  
Mortality and morbidity 
Mortality was pre-specified as a secondary endpoint in several studies. In the LIDO study, 
mortality was followed prospectively for 31 days following randomisation. At 31 days, 7.8% of 
patients assigned to levosimendan and 17.0% assigned to dobutamine had died (p=0.049). The 
follow-up was retrospectively extended to 180 days and the mortality rates were 26.2% with 
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Figure 6. Kaplan-Meier curves showing all-cause mortality during 180 days after 24-hour 
infusion of levosimendan or dobutamine in 203 patients hospitalized with low-output 
heart failure (the LIDO study). Hazard ratio 0.57; 95% CI 0.34 - 0.95, p=0.029 (453). 
In REVIVE I, mortality was prospectively followed for 31 and 90 days. The overall mortality 
rate was low, at 31 and 90 days mortality in the levosimendan group was 2% and 8%, 
respectively, compared with 8% and 10%, respectively, in the placebo group (454). In the 
CASINO study the mortality rate at 180 days in the levosimendan group (18.0%) was 
significantly lower than in both placebo (28.3%) (p=0.03) and dobutamine (42.0%) (p=0.0001) 
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groups (394). It is, however, important to consider that none of these trials were powered for 
mortality and therefore this positive evidence should be viewed as preliminary. 
In the LIDO study, a combined mortality/morbidity analysis was undertaken for a 180-day 
period following randomization, utilizing the endpoint “number of days alive and out of 
hospital”. It was revealed that patients in the levosimendan group spent significantly more days 
alive and out of hospital than dobutamine-treated patients (median 157 vs 133 days for 
levosimendan and dobutamine, respectively; p=0.027) (453). 
Anti-stunning effects 
The anti-stunning effects of levosimendan were evaluated in a randomized, double-blind study 
in patients with AMI who had undergone PTCA. The patients received levosimendan 24 µg/kg 
as a bolus dose (n=16) or corresponding placebo (n=8) 10 minutes after completion of the 
successful PTCA. The study showed that levosimendan improved the function of stunned 
myocardium, as shown by a reduction in the number of hypokinetic segments in the left 
ventricular wall compared with placebo (p=0.016) (458). 
Further support for an anti-stunning effect of levosimendan comes from an open-label study in 
20 patients with AMI and LVD. Various loading doses of levosimendan significantly improved 
contractility of the left ventricle both globally and in the infarcted region with wall motion 
abnormalities (459). 
Effects on diastolic function 
The effects of levosimendan on diastolic function were assessed using intracoronary infusions. 
Ten patients with heart failure received two doses without systemic effects (3.75 and 12.5 
µg/min) and dextrose (control) as bolus doses. In this study, τ, the time constant of left 
ventricular isovolumic relaxation, was unaffected by the lower dose of levosimendan. The 
higher dose of levosimendan produced a decrease in τ, indicating a mild positive lusitropic 
effect. Levosimendan had no significant effects on left ventricular (–)dP/dt (rate of fall of 
intraventricular pressure), another measure of diastolic function (460). 
In another randomized, placebo-controlled study, it was found that a 24-hour levosimendan 
infusion improves echocardiographic markers of abnormal left ventricular diastolic function 
(transmitral flow patterns and mitral annulus velocities, as assessed by transthoracic pulse-wave 
Doppler and tissue Doppler imaging, respectively) in patients with advanced heart failure (461). 
In a study in patients with AMI who had undergone PTCA the diastolic function was not 
worsened by levosimendan compared with placebo, while end-diastolic pressure-volume ratio 
and chamber compliance during late diastole changed similarly with levosimendan and placebo. 
In addition, τ was improved in the levosimendan group and impaired in the placebo group, 
which suggests improved diastolic function by levosimendan (458). 
Use in cardiac surgery 
The effects of levosimendan in patients undergoing cardiac surgery have been investigated so 
far in three studies. In one placebo-controlled study levosimendan was administered either as an 
18 µg/kg loading dose followed by an infusion of 0.2 µg/kg/min for 6 hours, or as 36 µg/kg 
followed by 0.3 µg/kg/min after cardiopulmonary by-pass in patients with normal preoperative 
cardiac function. Both levosimendan doses increased CO and stroke volume significantly and 
reduced peripheral vascular resistance. Levosimendan did not affect arterial oxygenation or 
cause arrhythmogenic effects and was well tolerated. The lower dose of levosimendan was as 
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effective as the higher dose, but it was associated with less hypotension and tachycardia, and 
was therefore considered to be a potential dose for use in this patient population. 
A placebo-controlled study with 2 bolus doses of levosimendan (8 and 24 µg/kg) in patients 
after cardiopulmonary by-pass showed that levosimendan transiently increased CO, reduced 
systemic and pulmonary vascular resistances, and did not adversely affect myocardial 
metabolism (462). Similarly, the bolus doses of 8 or 24 µg/kg did not increase myocardial 
oxygen consumption in these post-operative patients, although cardiac function improved 
markedly (462). 
An open-label study using only a bolus dose of 24 µg/kg in patients after cardiopulmonary by-
pass again showed that levosimendan transiently increased CO and stroke volume, and reduced 
systemic vascular resistance (463). Levosimendan did not impair isovolumic relaxation. An 
increase in coronary graft flow was observed. 
Safety 
Adverse events 
Headache and hypotension have been the most frequently reported adverse events in 
levosimendan-treated patients in placebo-controlled studies. Their incidence has been 2 to 9% 
for headache and approximately 5% for hypotension (450, 451). 
In the LIDO study, disturbances of heart rate and rhythm were reported with lower frequency in 
the levosimendan group than in the dobutamine group (3.9% versus 13.0%, respectively; 
p=0.023). Angina pectoris, chest pain and myocardial ischaemia was also reported less 
frequently with levosimendan than with dobutamine (0.0% versus 7.0%, respectively; p=0.013). 
Headache or migraine (13.6% versus 5.0%; p=0.052) and hypotension (8.7% versus 4.0%; 
p=0.252) were reported more frequently with levosimendan than with dobutamine (453). 
ECG and Holter findings 
The effects of levosimendan on conduction intervals have been modest. In the dose-finding 
study there were no changes in PQ or QRS intervals (450). The QTc interval (Bazett) was not 
prolonged at doses of 0.05 - 0.2 µg/kg/min, but the dose of 0.4 µg/kg/min increased heart rate 
by 10 bpm, and also prolonged QTc interval by 15 ms. An intracardiac electrophysiology study 
was conducted in 10 patients with normal cardiac function who were evaluated for rhythm 
disorders (464). Heart rate was kept constant by atrial pacing at various cycle lengths, 
corresponding to heart rates of 75 to 120 bpm. Levosimendan was given as a 10-minute loading 
dose of 18 µg/kg followed by a continuous infusion of 0.4 µg/kg/min for a total duration of 30-
40 minutes. The QT interval was unchanged compared with baseline at all studied cycle 
lengths. This indicates that levosimendan does not actually affect the duration of ventricular 
repolarisation. 
A meta-analysis of ambulatory ECG recordings was done on a total of 792 recordings pooled 
from 10 studies, with data from 386 patients. The recordings represented a total duration of >14 
000 hours. There were no significant differences between levosimendan and placebo in the 
occurrence of bradyarrhythmias, atrio-ventricular block or supraventricular or ventricular 
arrhythmias. New occurrence of supraventricular or ventricular tachycardia or other 
proarrhythmia according to Morganroth criteria was similar during levosimendan and placebo 
administration (465). 
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Studies with oral levosimendan 
The haemodynamic effects of an oral formulation of levosimendan were evaluated in a pilot 
study in 10 patients with NYHA IIIb-IV heart failure. The patients had a mean baseline PCWP 
of 22 mmHg and LVEF of 23%. The study was open and uncontrolled, with 3 escalating single 
doses. Each patient was given 1 mg as the first dose, 2 mg 6 hours later, and 4 mg 18-24 hours 
later. After 1 mg, PCWP decreased by 18% (p=0.002), CO increased by 22% (p=0.005), while 
HR increased by 3-8 bpm (Figure 7). Systolic BP did not change, while dBP dropped by about 
5 mmHg. The effects after 2 mg were small, which was probably due to a meal served to the 
patients before drug intake, which could have delayed the absorption of the drug and altered 
baseline haemodynamics. After 4 mg CO increased by 27% compared to baseline (p=0.009), 
while HR increased by 1-3 bpm. Systolic BP increased by 7-9 mmHg, while dBP was virtually 
unchanged. PCWP showed only a small decrease, probably due to rather low baseline values 
(carry-over from previous doses). Also pulmonary artery pressure decreased slightly. However, 
right atrial pressure decreased substantially by 28-40% after 4 mg. All doses were well 
tolerated. The study suggested that oral levosimendan is haemodynamically beneficial, the 
effects resembling those seen after intravenous administration (466). 















Figure 7. Effects of a single oral dose of 1 mg of levosimendan on cardiac output (CO), 
pulmonary capillary wedge pressure (PCWP), and heart rate (HR) in 10 patients with 
severe heart failure. Percent changes from baseline (BL) values are shown. 
In order to determine the efficacy of multiple dosing of oral levosimendan in severely ill 
patients, 24 patients with end-stage heart failure, who were dependent on i.v. inotropic support, 
were enrolled in an open-label pilot study. Dependence on i.v. inotropic therapy was defined as 
inability to wean the patient from i.v. inotropic support without clinical decompensation on two 
separate occasions within a two-week period. The mean LVEF was 24% at baseline. 
The patients were administered oral levosimendan at escalating doses to the maximum tolerated 
dose concomitantly with a stable dose of an i.v. inotrope for the first 2 days (Day 1-2). From 
then on, the i.v. inotropic agent was tapered over 3 days (Day 3-5). After successful 
discontinuation of the i.v. inotropic agent, the dose of oral levosimendan was reduced to one-
half, and maintained at this level through Day 10 after starting levosimendan. After Day 10 the 
patients who were successfully weaned from i.v. inotropic therapy were allowed to continue 
their oral treatment with levosimendan. The weaning was considered successful if: (1) the i.v. 
inotrope was tapered by Day 5, and (2) the patient remained off these agents for 5 additional 
days (until Day 10). 
Of the 24 patients enrolled, 20 were successfully weaned from i.v. inotropic support 
(dobutamine or milrinone). Ejection fraction was unchanged between screening and Day 10. 
About 50% of the patients experienced improvement or no change in their clinical signs and 
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symptoms of heart failure by Day 10. After Day 10, 7 patients continued on oral levosimendan 
more than 90 days during optional follow-up. The average duration of long-term therapy was 
71 ± 65 days and average dose 1 mg two or three times daily (467). 
This study suggested that oral levosimendan may be useful as a substitute for i.v. inotropic 
agents in patients with severe heart failure who are unable to be withdrawn from these agents, 
thus allowing the patients to be managed out of hospital. 
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3. Aims of the study 
Previous clinical experience with levosimendan has suggested that levosimendan is effective 
and well-tolerated in patients with severe congestive heart failure. Very often, however, the 
decompensation of heart failure occurs as a consequence of acute or chronic ischaemia. The 
experience in patients with acute ischaemia has been very limited and the risk-benefit profile of 
the drug in this setting has not been characterised. In addition, the information about the 
efficacy and safety of oral levosimendan has been obtained only from open label studies and no 
placebo-controlled evaluation of oral levosimendan has been performed in patients with 
ischaemia or ischaemic heart failure. 
The aim of the thesis can be summarised as follows: 
1) To study the safety and efficacy of intravenous levosimendan in patients with acute IHD - 
AMI, complicated by left ventricular failure (Study I) 
2) To characterise the pharmacodynamic effects and pharmacokinetic-pharmacodynamic 
interrelationships of intravenous and oral levosimendan in patients with ischaemia or 
ischaemic heart failure (Study II and Study III) 
3) To characterise the pharmacodynamic effects of long-term administration of oral 
levosimendan in patients with ischaemia or ischaemic heart failure (Study III and Study IV) 
4) To characterise the pharmacokinetics of oral levosimendan and its metabolites in patients 
with ischaemic heart failure (Study IV) 
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4. Subjects and methods 
The four publications included in this thesis are based on three different studies. Reference to 
the four publications is made in the text as studies I, II, III and IV, as summarised below: 
Study I (publication I) 
• Study in 504 patients experiencing AMI complicated by left ventricular failure 
• Four different 6-hour intravenous infusions of levosimendan were administered  
Study II (publication II) 
• Study in 29 patients with chronic heart failure due to IHD 
• Levosimendan was administered as 6-hour intravenous infusion and as single oral dose 
Study III (publication III) 
• Study evaluating pharmacodynamic effects of oral levosimendan and its interactions with 
felodipine in 24 patients with chronic IHD 
• Levosimendan was administered four times daily 
Study IV (publication IV) 
• Study investigating pharmacodynamics and pharmacokinetics of oral levosimendan and its 
metabolites in 25 patients with chronic heart failure due to IHD 
• Levosimendan was administered in 4 different daily doses and 4 different dosing intervals 
4.1 Study subjects 
A total of 557 patients were included in this thesis (Table 12). Most of the patients participating 
in study II, participated also in study IV, so that the population of study IV represents actually 
a subpopulation of study II. Almost all patients in all studies experienced different forms of 
IHD, which was complicated by acute left ventricular failure or chronic heart failure (except in 
study III). Study I was performed in 21 centers in Russia and Latvia, while studies II-IV were 
performed in Mustamäe Hospital, Tallinn, Estonia. 
Since the studies had relatively different objectives, several important differences can be noted 
also between the study populations. Study I investigated the effects of levosimendan in the 
acute setting, whereas studies II-IV evaluated the effects of the drug in patients with a chronic 
form of IHD or heart failure and required a clinically stable condition. Therefore, the criteria for 
exclusion used in studies II-IV were rather similar, except for the existence of heart failure, 
which was actually an inclusion criterion for studies II and IV and exclusion criterion for 
study III. Patients with bradycardia, tachycardia, history of supraventricular or ventricular 
tachycardia, ventricular flutter or fibrillation, second or third degree atrioventricular (AV) 
block, valvular disease, severe hyper- or hypotension, obesity, relevant renal or hepatic failure 
and chronic pulmonary or endocrinological disease were excluded from those three studies. 
Study I included patients with recent AMI complicated by left ventricular failure, evidenced by 
pulmonary venous congestion or pulmonary oedema on chest X-ray and clinical need for 
inotropic therapy on the basis of symptomatic heart failure despite conventional therapy. 
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Specifically, the study was designed to evaluate whether the pharmacological actions of 
levosimendan would be well tolerated in acutely ill patients with unstable heart failure due to an 
AMI who had a clinical need for positive inotropic therapy. Positive inotropic agents have been 
reported to produce serious hypotension and worsening ischaemia in these patients, and thus, 
these two safety variables were selected as the primary outcome measures for this study. As in 
studies II-IV, patients with severe arrhythmic disorders, hypotension or hepatic failure were 
excluded from study I, but as to renal failure, only patients with severe renal failure were 
excluded. Other exclusion criteria, such as myocardial rupture or severe mitral valve 
insufficiency, cardiac tamponade, use of beta-adrenergic agonists within 30 minutes before the 
start of the study, septic shock and agonal status underline the severity and acuteness of the 
investigated patients. 











Main diagnosis AMI + LVF CHF IHD CHF 
Age, years (mean ± SEM) 67 ± 11 58 ± 2 57 ± 2 57 ± 4 




260 (52)  
244 (48) 
 








Weight, kg 77 ± 13 76 ± 2 84 ± 1 76 ± 4 
NYHA/CCS/Killip class II-III (Killip) III-IV (NYHA) II (CCS) III-IV (NYHA) 
Ischaemic heart disease, N (%) 504 (100) 25 (86) 24 (100) 21 (84) 
Hypertension, N (%) 338 (67) 5 (17) 5 (21) 5 (20) 
Atrial fibrillation, N (%) 29 (6) 6 (21) 0 (0) 7 (24) 
Gastrointestinal disease, N (%) 126 (25) 3 (10) 3 (13) 2 (8) 
Pulmonary disease, N (%) 121 (24) 0 (0) 0 (0) 0 (0) 
Diabetes mellitus, N (%) 97 (19) 3 (10) 1 (4) 2 (8) 
Cerebrovascular disease, N (%) 72 (14) 1 (4) 0 (0) 0 (0) 
HR, bpm (mean ± SEM) 82 ± 4 72 ± 3 70 ± 2 70 ± 5 
SBP, mmHg (mean ± SEM) 125 ± 5 121 ± 2 140 ± 3  121 ± 6 
DBP, mmHg (mean ± SEM) 75 ± 3 78 ± 2 85 ± 2 75 ± 3 
Use of selected drugs     
Thrombolytics, N (%) 86 (17) 0 (0) 0 (0) 0 (0) 
Nitrates, N (%) 487 (97) 22 (76) 18 (75) 19 (76) 
ACE inhibitors, N (%) 237 (47) 26 (90) 0 (0) 23 (92) 
Beta-blockers, N (%) 196 (39) 9 (31) 16 (67) 8 (32) 
Calcium antagonists, N (%) 66 (13) 2 (7) 0 (0) 2 (8) 
Diuretics, N (%) 376 (75) 14 (48) 0 (0) 18 (72) 
ASA, N (%) 444 (88) 24 (83) 20 (83) 23 (92) 
Heparin and analogues, N (%) 427 (85) 1 (3) 0 (0) 1 (4) 
Cardiac glycosides, N (%) 66 (13) 18 (62) 0 (0) 16 (64) 
I.v inotropes, N (%) 72 (14) 1 (3) 0 (0) 0 (0) 
Antiarrhythmics, N (%) 129 (26) 4 (14) 1 (4) 4 (16) 
Mean age in studies II-IV was about 57 years, but in study I it was higher, being about 67 
years. In studies II-IV most of the patients were male, whereas in study I almost half of the 
patients were women. In all studies most of the patients suffered from IHD. Mean weight was 
rather similar in all studies. All patients were Caucasian. 
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The studies are different regarding severity and acuteness disease of the patients, which is 
reflected in the baseline characteristics. Patients in study I had a much more severe and acute 
form of the disease and also their basic health condition was more complicated, which is 
characterized by the higher number of concomitant diseases. For example, hypertension was 
present in 67% of patients in study I, whereas in the other studies only about 20% of patients 
suffered from hypertension. The incidence of gastrointestinal disease, pulmonary disease, 
cerebrovascular disease and diabetes was also higher in study I. This can partly be explained by 
the fact that severe forms of those diseases were exclusion criteria in studies II-IV, which 
obviously limited the frequency of also mild forms. 
In all studies study treatment was administered in addition to the patients’ normal medication 
for IHD and heart failure. Only in study III, which was also an interaction study with 
felodipine, were calcium antagonists prohibited from patients. There are some differences 
between the studies regarding concomitant medication such as ACE inhibitors, which were 
more frequently administered in studies II and IV. The absence of concomitant ACE inhibitors 
and the relatively high frequency of beta-blockers in study III are related to the absence of 
concomitant heart failure. The same applies to the use of diuretics. Nitrates and ASA were 
administered in similar frequency in all studies, while thrombolytics and heparin were 
administered solely in study I as treatment of AMI. 
The haemodynamics at baseline were relatively similar in all studies. Heart rate was higher at 
baseline in study I and blood pressure in study III. Despite higher incidence of hypertensive 
patients in study I, baseline blood pressure values in that study were relatively low, which can 
be explained by severe left ventricular failure and depression of the pump function of the heart 
in those patients. 
4.2 Study designs 
Study I 
Study I was a randomized, parallel-group, placebo-controlled and double-blind study. Five 
hundred and four patients were recruited between June 1996 and December 1998, and the 
follow-up was completed in April 2000. A computer-generated randomisation schedule, based 
on permuted blocks and balanced within each centre, was used to allocate patients to placebo or 
one of four dose regimens of levosimendan (Figure 8). The loading dose was infused over a 
period of 10 minutes and the continuous infusion was maintained for 5 hours and 50 minutes. 
All the formulations and vials were made to look identical and contained either no active 
ingredient or different amounts of levosimendan. The volumes infused into the patients of the 
five different treatment arms were also identical. Study medications were introduced via a 
peripheral vein using a calibrated infusion pump. 
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Urine output (2h fractions) 
LS 0.1 µg/kg/min 
LS 0.4 µg/kg/min 
Placebo 
LS 0.2 µg/kg/min 
LS 0.2 µg/kg/min 
LS 24 µg/kg 
LS 12 µg/kg 
LS 24 µg/kg 
LS 6 µg/kg 
Rz 
If needed, dopamine 3-9 µg/kg/min is added 
Time 0 10 30  40 60  70 min     2 h 4 h 6 h 8 h            24 h 14 d
Symptoms x x 
Chest X-ray* x x 
BP/HR x x x x x x x x x x 
ECG x x x x x x x x x x 
Adverse events x x 
CK-MB x x 
Survival x
*The chest x-ray was taken 0-6 hrs before time 0 and repeated 12-30 hrs after the start of the infusion. 
Continuous Infusion (5 h 50 min) 
Placebo 
 
Figure 8. Design of study I 
Investigators were mandated to stop the infusion of the study medication at any time if the 
patients experienced any of the following: symptomatic hypotension, heart rate >130 bpm 
sustained for 10 min, or any serious adverse event. Patients were permitted to receive all 
appropriate therapy for the management of both AMI and heart failure. Patients developing 
persistent hypotension or refractory heart failure during infusion were permitted intravenous 
dopamine (3-9 µg/kg/min). 
Throughout the 6-hour infusion period, patients were assessed for hypotension or myocardial 
ischaemia of clinical significance, symptoms of heart failure, haemodynamics, urinary output 
and adverse events. In addition to spontaneous reporting, an adverse event inquiry was 
undertaken by the investigator at the end of infusion and at 24 hours after start of infusion. 
Survival of the patients was evaluated at 14 days following the start of infusion. An additional, 
retrospective 180-day mortality follow-up was conducted after the end of the study. Blood 
samples drawn before the start of infusion and immediately after infusion were used to 
determine serum CK-MB levels. A chest X-ray was repeated within 12-30 hours after start of 
infusion. 
Study II 
Study II was a two-day open-label, non-randomized trial in 29 patients with NYHA class III-
IV chronic heart failure. On the first day patients were given a 6-hour levosimendan infusion 
with the dose 0.2 µg/kg/min. After a 1-week washout the patients received a 2 mg single oral 
dose of levosimendan. 
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Study III 
Study III was a randomized, double-blind, placebo-controlled, crossover study in 24 male 
patients with Canadian Cardiovascular Society (CCS) class II IHD. The study consisted of four 
treatment periods, each period lasting for 7-10 days. In the first period the patients received 
either oral levosimendan (0.5 mg) or placebo four times daily and were then crossed over to the 
other therapy for the second and third periods. After the third period the patients were changed 
back to the therapy administered in the first period. Open label felodipine, 5 mg once daily, was 
co-administered on the third and fourth treatment periods (Figure 9). 
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Figure 9. Design of study III 
Study IV 
Study IV was a randomized, parallel-group, double-blind and placebo-controlled study in 25 
patients with NYHA class III-IV chronic heart failure. Each patient received an ascending dose 
of study medications on two consecutive two-week periods without a washout (Figure 10). 
Patients were randomized to three groups according to the method of sequential treatment 
design as follows: 
• Group I (“low-dose” group, n=9) received levosimendan 2 mg x 1 for two weeks, and then 2 
mg x 3 for two more weeks. 
• Group II (“high-dose” group, n=8) received levosimendan 2 mg x 2 for two weeks, and then 
2 mg x 4 for two more weeks. 
• Group III (placebo group, n=8) received placebo during both study periods. 
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Figure 10. Design of study IV 
4.3 Assessments 
4.3.1 Haemodynamics 
Non-invasive haemodynamic measurements were used in all studies. 
Study I 
Blood pressure and heart rate were measured at baseline, and at 10, 30, 40, 60 and 70 minutes 
and then at 2, 4 and 6 hours after the start of infusion, and finally, 2 hours after discontinuation 
of the study drug. For assessment of heart rate a 12-lead ECG was used at baseline and at 6 
hours, while at other time points either rhythm strips or limb lead ECGs were used. 
Studies II-IV 
The effect of levosimendan on haemodynamics was evaluated using assessments of systolic 
time intervals, blood pressure and heart rate. 
For determination of systolic time intervals ECG, carotid artery pulse curve and 
phonocardiogram were recorded simultaneously (Schiller CS-100, Schiller AG, Switzerland). 
Electromechanical systole (QS2) was measured from the beginning of the Q-wave in the ECG 
to the beginning of the aortic component of the second heart sound. Five to ten cardiac cycles 
were averaged using a digitizer. QS2 was corrected for heart rate according to the formula: 
QS2i = QS2 + 2.1 x heart rate. The digitizing of QS2 was performed by a person independent of 
the study team. 
Blood pressure was measured by an automatic oscillometric device (Omron M4, model HEM-
722C, Omron Matsusaka Co., Japan) and heart rate from ECG recordings. 
In study II, on the first study day haemodynamics was assessed at -20 min (baseline), and at 
0.5, 1, 2, 4, 6, 6.5, 7, 8 and 10 h. During the second study day QS2i-, HR- and BP-assessments 
were made at -20 min (baseline), and at 1, 2, 3, 4, 5, 6 and 8h. 
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In study III systolic time intervals were measured at -30 min, and at 1, 3 and 7 h, blood 
pressure and heart rate at –30 min, and at 1, 2, 3, 4, 5 and 6 h on first and the last day on each 
treatment period. 
In study IV haemodynamics was assessed at baseline and on the last day of both treatment 
periods at -20 min, and at 2, 4 and 8 h. 
4.3.2 Symptoms and signs 
Symptoms and signs were only assessed in study I. Dyspnoea, fatigue, jugular venous 
distension, peripheral oedema and anginal pain were assessed before the administration of the 
study drug and at the end of the 6-hour treatment period. 
The following scales were utilized for evaluation of symptoms: 
- dyspnoea, fatigue and anginal pain: none, slight, moderate, marked and disabling 
- jugular venous distension: none; at <45° elevation; at >45° elevation 
- peripheral oedema: none, present. 
Increase in symptom score was categorised as worse, decrease as better, and no change as 
unchanged. In the worst-rank symptom analysis, patients were considered to be worse if, in 
addition to the changes in actual dyspnoea and fatigue scores during the 6-hour study infusion, 
they (1) died; (2) developed worsening heart failure; or (3) received a new drug for the 
treatment of heart failure. 
In order to determine the degree of pulmonary congestion, a chest x-ray was performed within 6 
hours before administration of the study drug and 12-30 hours after start of infusion of study 
drug. Responses were ranked as: 
- normal (equal distribution of blood flow in lower and upper lobes); 
- pulmonary venous congestion (redistribution of pulmonary blood flow to upper lobes); 
- pulmonary venous congestion with interstitial oedema; 
- pulmonary venous congestion with alveolar oedema. 
4.3.3 Morbidity and mortality 
Morbidity and mortality as endpoints (combined risk of death and worsening heart failure) were 
assessed in study I during the first 6 hours and during 24 hours after start of infusion. Mortality 
alone was assessed over 14 days after start of infusion. The mortality follow-up was prolonged 
retrospectively to 180 days, using information from Official Inhabitants’ Registries and hospital 
files. 
The term “worsening heart failure” was predefined for characterisation of all possible major 
clinical events that may occur in this patient population. Patients were considered to have 
worsening heart failure if they experienced onset or worsening of any of the following 
conditions: dyspnoea, fatigue, pulmonary congestion or oedema, heart failure or cardiogenic 
shock. 
4.3.4 Exercise test 
Exercise test was used in studies III and IV. In study III, at the end of each treatment period, a 
symptom-limited exercise test was undertaken on a bicycle ergometer. The initial load was 50 
W, which was increased by 25 W at 3-minute intervals until subjective maximum. Indications 
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for stopping of the exercise test were severe exhaustion, severe dyspnoea, severe angina 
pectoris (Borg scale 4-5 out of 10), dizziness, ST-displacement >2 mm, persistent drop in sBP, 
serious ventricular arrhythmias, supraventricular tachycardia or AV block. During the test and 
immediately before its termination heart rate, blood pressure and magnitude of changes of ST-
segment (at the end of each workload and upon the termination of the test) were measured. 
Total exercise time and highest achieved workload were recorded. ST-depression was measured 
60 ms from J-point. 
In study IV, a six-minute walk test was performed at baseline and on the last day of each 
treatment period. The walk test was carried out as follows: the patient walked for 6 minutes at 
his/her own pace from end to end in a corridor of 30 m. The patients were not encouraged 
during the test, and they were allowed to take pauses, if symptoms so required. The walked 
distance was measured to the nearest 5 m. 
4.3.5 Pharmacokinetics 
Sampling 
No pharmacokinetic samples were drawn in study I. Drug and metabolite concentrations were 
measured in study III and pharmacokinetic variables were calculated in studies II and IV. 
On the first day in study II the venous blood samples for determination of levosimendan 
concentrations in plasma were drawn at -20 min (baseline), and at 0.5, 1, 2, 4, 6, 6.5, 7, 8 and 
10 h. On day two samples were drawn at -20 min (baseline), and at 0.5, 1, 2, 3, 4, 5, 6 and 8 h. 
In study III, samples for measurement of levosimendan concentrations were drawn at one hour 
after each capsule intake during the visit on the last day of each treatment period (at 1, 4 and 7 
h). A plasma sample for measurement of concentrations of levosimendan metabolites was 
drawn on the last day of each treatment period. 
In study IV, on the last day of each treatment period, venous blood samples for determination 
of levosimendan concentrations were drawn at -20 min, and at 2, 4 and 8 h. Metabolite 
concentrations were determined from the samples drawn at -20 min, and at 2 and 8 h and also 
from a sample drawn one week after the last medication day of the second treatment period 
(day 35). 
Analyses 
The concentrations of levosimendan in plasma were determined by an automated sample 
preparation technique with reversed-phase high performance liquid chromatography with UV 
detection (468). The method gave linear and interference free results over a plasma 
concentration range from 5 to 500 ng/ml. The within-run precision was <15% at the 
quantitation limit (5 ng/ml) and <5% at higher concentrations. The between-run precision was 
<10% at concentrations up to 50 ng/ml and <5% at higher concentrations. The concentrations of 
levosimendan metabolites, OR-1855 and OR-1896, in plasma were determined by liquid 
chromatography-tandem mass spectrometry using the selected reaction monitoring technique. 
The method gave linear and interference free results. The within-run precision was <11% at the 
quantitation limit (0.1 ng/ml) and <8% at higher concentrations. The between-run precision was 
<9% at concentrations up to 0.6 ng/ml and <7% at higher concentrations. Individual plasma 
concentration-time data of levosimendan were analyzed using a standard noncompartmental 
method in WinNonlin® Professional computer program (Version 3.1, Pharsight Corporation, 
USA). 
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In study II a model-independent method was used to determine pharmacokinetic parameters of 
levosimendan in plasma. Individual plasma concentration-time data of levosimendan was 
analysed using a standard noncompartmental method in WinNonlin® Professional computer 
program (Version 3.1, Pharsight Corporation, US). Peak plasma concentration (Cmax) and time 
of peak plasma concentration (tmax) were obtained directly from the plasma concentration-time 
data. The terminal elimination rate constant (λz) was obtained directly from the regression 
analysis with visual inspection of the data to determine the number of points in the terminal 
elimination phase. Terminal elimination half-life (t1/2) and total plasma clearance (Cltot) were 
calculated. 
The area under the plasma concentration-time curve was calculated from the beginning of the 6-
hour infusion to the last detectable concentration using the linear trapezoidal method (AUClast). 
The area was also extrapolated to infinity (AUC∞). The apparent volume of distribution based 
on the terminal phase (Vz) and the apparent volume of distribution at steady-state (Vss) were 
calculated. Mean residence time (MRT) was determined. 
The following pharmacokinetic parameters were calculated for levosimendan after the 2 mg 
single oral dose: Cmax, tmax, λz, t1/2, AUClast and AUC∞. Bioavailability of oral levosimendan 
was calculated using the following formula: FA = (Div / Do) x (AUC∞,Do / AUC∞,Div) x 100%, 
where Div refers to the total dose of levosimendan, administered during the intravenous infusion 
and Do refers to the 2 mg single dose of oral levosimendan. 
In study IV, peak plasma concentration (Cmax) and time to peak plasma concentration (tmax) of 
levosimendan were obtained directly from the plasma concentration-time data. The area under 
the plasma concentration-time curve was calculated from the intake of the first capsule of the 
day to the last detectable concentration using the linear trapezoidal method (AUClast). 
Pharmacokinetics of levosimendan metabolites was analysed on the last day in both study 
periods. Cmax and AUC8h were calculated for OR-1855 and OR-1896 using a standard 
noncompartmental method. 
4.3.6 Safety 
Ischaemia and hypotension in study I 
Study I was designed as a safety study in patients with AMI complicated by left ventricular 
failure. The primary endpoint of the study was the proportion of patients developing 
hypotension or ischaemia of clinical significance as adjudicated by an independent Safety 
Committee. Clinically significant hypotension was defined as: (1) symptomatic hypotension 
(obligatory) or (2) asymptomatic drop of sBP by more than 10 mmHg (at the discretion of the 
investigator). Clinically significant ischaemia was defined as: (1) aggravation or a new onset of 
anginal pain; or (2) further depression or elevation of ST-segment by more than 1 mm in 12-
lead ECG. 
Clinically significant hypotension and/or ischaemia, reported by the investigator, was evaluated 
by the Safety Committee. For this evaluation, investigators provided the Safety Committee with 
the Case Records Forms, ECGs and copies of patients’ hospital files (as necessary). The Safety 
Committee held meetings after every 100 recruited patients. Members of the Safety Committee 
were unaware of patient treatment allocation at the time of evaluation. 
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Adverse events 
In addition to spontaneous reporting, an adverse event inquiry was undertaken by investigator 
in all studies. In study I adverse event follow-up was carried out during the 24 hours after start 
of study drug infusion. In study II adverse event follow-up was carried out during 24 hours 
after start of administration of study medication. In studies III and IV, adverse events were 
followed during the treatment periods and in study IV an additional follow-up was carried out 
also at one week after the last medication day of the second treatment period. 
Safety laboratory variables 
For assessments of safety laboratory variables, in studies II-IV the local hospital laboratory 
was used, while in study I a central laboratory analyzed the samples. 
In study I samples for determination of CK-MB were taken at baseline and at the end of the 6-
hour infusion. In study II, samples were taken on both study days at baseline and at 24 h. In 
studies III and IV samples were taken at baseline and at the end of treatment periods. 
In studies II-IV the following haematological and biochemical markers were determined: 
blood (B)-Erythrocytes, B-Glucose, B-Haematocrit, B-Haemoglobin, B-Leukocytes, B-
Thrombocytes, serum (S)-Alanine aminotransferase, S-Alkaline phosphatase, S-Aspartate 
aminotransferase, S-C-reactive protein, S-Creatinine, S-Gammaglutamyltransferase, S-
Potassium, S-Sodium, urine (U)-Glucose, U-Protein. 
Holter monitoring 
For detection of clinically relevant arrhythmic and ischaemic disorders 24-hour ambulatory 
ECG recording (Holter) was undertaken in studies II-IV. The recordings were measured using 
the Holter Recorder Marquette device (Series 8500, Marquette Electronics, Inc., Milwaukee, 
WI, USA). In study II Holter recordings were carried out at baseline and during both study 
days. In studies III and IV recordings were carried out at baseline and on the last day of each 
treatment period. 
The occurrence of relevant arrhythmic disorders such as ventricular fibrillation, sustained 
ventricular tachycardia (duration >30 seconds, frequency >120 bpm) and runs of ventricular 
and supraventricular tachycardia (duration ≥ 3 beats, frequency >120 bpm) and episodes of 
bradyarrhythmia were registered. For evaluation of ischaemia, ST-segment deviations were 
represented in a 24-hour trend diagram and verified with a 50-mm/s electrocardiogram printout. 
Typical ischaemic change was defined as a transient horizontal or descending ST-depression ≥ 
0.1 mV (measured 80 ms from J-point) that lasted at least 1 minute. Transient ST-elevations 
were evaluated in the same manner with the precondition that they did not occur in leads with 
pathological Q-waves. The time between episodes had to be at least 1 minute. The total 
duration and number of ischaemic episodes and the longest ischaemic episode were recorded. 
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4.4 Statistical methods 
In all studies statistical analyses were based on the intention-to-treat principle, performed at a 
two-sided 0.05 level of significance. Analyses were carried out using SAS 6.12 statistical 
software (SAS Institute Inc., Cary, NC, US) for Windows. 
Study I 
Baseline characteristics were summarised using appropriate descriptive statistics; values for 
each characteristic were compared among the five treatment groups by using Analysis of 
Variance (ANOVA) with effects for treatment, centre and treatment by centre interaction or the 
non-parametric Cochran-Mantel-Haenszel (CMH) test, controlling for centre. In analyses for 
primary endpoint the differences between the five treatment groups and between the placebo 
group and pooled levosimendan group the proportions of patients were tested using the CMH 
row mean scores test, controlling for centre. The relationship between dose and frequency of 
event(s) was evaluated using the CMH non-zero correlation test. 
Combined risk of death and worsening heart failure was expressed using a time-to-event model. 
The log-rank test was used for detecting differences between placebo and pooled levosimendan 
groups. Cumulative survival curves for placebo and pooled levosimendan groups were 
constructed by the Kaplan-Meier method and the differences between the curves were tested for 
significance using the Cox proportional hazards model. Survival time in the model was 
calculated as the difference in days from the start of infusion to the event or to the last follow-
up date. The relationship between dose and frequency of event(s) was evaluated using the CMH 
non-zero correlation test, controlling for centre. 
Changes in symptoms, jugular venous distension, peripheral oedema, urinary output, pulmonary 
congestion and CK-MB values were evaluated using ANOVA methods or by use of CMH row 
mean scores test, controlling for centre. The frequency of adverse events in the five treatment 
groups was compared using Fisher's exact test. Dose-relations of adverse events were tested 
using the CMH non-zero correlation test, controlling for centre. 
Study II 
Changes in haemodynamics were evaluated by repeated measures ANOVA. Descriptive 
concentration-effect loops between QS2i, heart rate, sBP, dBP and levosimendan 
concentrations as a function of time were constructed. Descriptive statistics was applied for the 
pharmacokinetic parameters, safety laboratory parameters and for Holter recordings. 
Study III 
Results of haemodynamics and Holter recordings on the last day of each treatment period were 
evaluated statistically by univariate repeated measures ANOVA models, which included both 
random and fixed effects (MIXED-procedure). The possible carry-over effect was evaluated by 
comparing the two sequences (LS and PL vs PL and LS; LS+FD and PL+FD vs PL+FD and 
LS+FD) using the two-sample t-test. 
Study IV 
The changes in haemodynamics and in the 6-minute walk test from baseline to 2 hours on the 
last treatment day of the study period were compared between the three treatment groups in the 
two study periods separately using ANOVA with effect for treatment. Descriptive statistics was 
applied for the safety laboratory and pharmacokinetic parameters. The relationship between 
levosimendan dose and metabolite concentrations was tested using the paired t-test. The 
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relationship between the pharmacokinetic parameters of levosimendan and its metabolites and 
daily dose were examined by using linear regression analyses. Changes in ECG parameters 
were compared between the three treatment groups in the two study periods separately using 
one-sample t-test and ANOVA methods and changes in Holter parameters by using the 
Cochran-Mantel-Haenszel test. 
4.5 Ethics 
The studies were conducted according to the Declaration of Helsinki of the World Medical 
Assembly and its amendments. The study protocols and any relevant amendments were 
reviewed and approved by the local Ethics Committees and Regulatory Authorities. Written 






At 30 minutes following the start of treatment, there were similar minor changes in sBP 
(p=0.84) and dBP in all treatment groups (p=0.20). In contrast, at the end of the 6-hour double-
blind treatment period, levosimendan produced dose-dependent decreases in systolic and dBP 
(p=0.001). The changes in blood pressure at 6 hours were relatively modest with the three 
lowest infusion rates of levosimendan (placebo-corrected decreases in systolic and dBP of up to 
4 and 2 mmHg, respectively). The highest infusion rate of levosimendan (24 µg/kg + 0.4 
µg/kg/min), however, produced placebo-corrected decreases in sBP and dBP of up to 7 mmHg 
(Table 13). 
Levosimendan increased heart rate dose-dependently at both 30 minutes and 6 hours (p=0.001). 
At 30 minutes, patients who received a 6 or 12 µg/kg loading dose had only small increases in 
heart rate (1-2 bpm), whereas patients who received the largest loading dose (24 µg/kg) showed 
6-7 bpm increases in heart rate (corrected for placebo). Similarly, at 6 hours, the changes in 
heart rate were relatively modest with the three lowest infusion rates of levosimendan (up to 4 
bpm). In contrast, the highest infusion rate of levosimendan (24 µg/kg + 0.4 µg/kg/min) 
produced an increase of over 11 bpm in heart rate (Table 13). 
Table 13. Baseline values and changes in blood pressure and heart rate at 30 minutes and at 6 
hours (end of infusion). Mean (SEM) are given. 
 Placebo 
(n=102) 
LS 6 µg/kg + 
0.1 µg/kg/min 
(n=103) 
LS 12 µg/kg + 
0.2 µg/kg/min 
(n=100) 
LS 24 µg/kg + 
0.2 µg/kg/min 
(n=99) 
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*p=0.012 for dose-relation; † p=0.001 for dose-relation 
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Study II 
Both sBP and dBP decreased from baseline at the end of the 6-hour infusion. Heart rate 
remained stable, after both the 6-hour infusion and 2 mg oral dose. Changes in blood pressure 
after intake of the 2 mg capsule were smaller than after the 6-hour infusion. QS2i shortened 
both after the 6-hour infusion and after intake of the 2 mg capsule (Table 14). 
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Figure 11. Concentration-effect loops for QS2i, sBP and dBP after 6-hour intravenous infusion 
and 2 mg single oral dose of levosimendan. 
Study III 
Oral levosimendan, administered 0.5 mg four times daily increased heart rate in comparison 
with placebo and felodipine, while felodipine decreased sBP in comparison with both 
levosimendan and placebo. The differences between treatments regarding heart rate and sBP 
were statistically significant (p<0.001 and p=0.003, respectively). Changes in dBP were small 
(p=0.26). 
Levosimendan shortened QS2i by 10 ms (95% CI [-15, -4]), compared with placebo, indicating 
a moderate positive inotropic effect. The difference between treatments was statistically 
significant (p<0.001). The results were similar when levosimendan was administered 
concomitantly with felodipine. Pairwise comparisons of haemodynamic parameters on the last 
day of the treatment period are presented in Table 15. 
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Table 15. Pairwise comparisons of QS2i, heart rate and blood pressure on the last day of the 
treatment period. Dose of oral levosimendan 0.5 mg four times daily, and that of 
felodipine 5 mg daily. 
  Mean difference 95% CI 
QS2i (ms) LS vs PL -10 [-15; -4] 
 FD vs PL +1 [-5; +6] 
 LS + FD vs LS +3 [-3; +8] 
 LS + FD vs FD -8 [-14; -2] 
HR (bpm) LS vs PL +6 [+3; +9] 
 FD vs PL +2 [-1; +6] 
 LS + FD vs LS +3 [0; +6] 
 LS + FD vs FD +7 [+3; +10] 
sBP (mmHg) LS vs PL +2 [-2; +5] 
 FD vs PL -4 [-8; -1] 
 LS + FD vs LS -5 [-8; -2] 
 LS + FD vs FD +1 [-2; +5] 
dBP (mmHg) LS vs PL 0 [-1; +2] 
 FD vs PL -1 [-3; +1] 
 LS + FD vs LS -2 [-3; 0] 
 LS + FD vs FD 0 [-2; +2] 
Study IV 
Levosimendan given at 2 mg daily did not cause an increase in heart rate after 14 days of 
administration, the effect being similar to placebo. After 4-8 mg daily doses of levosimendan 
heart rate increased by 8-11 bpm. Interestingly, no further increase in heart rate was seen in the 
high-dose group when the daily dose was doubled. The differences between the treatment 
groups regarding change in heart rate after both first and second treatment periods were nearly 
significant (p=0.09 and p=0.05, respectively) (Table 16). 
Changes in blood pressure were small. Systolic BP decreased by 2 mmHg after the 2 mg daily 
dose and by 1 mmHg after the 6 mg daily dose compared with the baseline. After the 4 mg 
daily dose sBP increased by 5 mmHg and after the 8 mg daily dose it decreased by 2 mmHg. In 
the placebo group sBP decreased by 5 mmHg. The differences between the treatment groups 
regarding change in sBP after both first and second treatment periods were not significant 
(p=0.15 and p=0.40, respectively) (Table 16). 
Small changes were seen also regarding dBP. Diastolic BP decreased by 1 mmHg after the 2 
mg daily dose and by 6 mmHg after the 6 mg daily dose compared with baseline. After the 4 
mg daily dose dBP increased by 1 mmHg and after the 8 mg daily dose it decreased by 2 
mmHg. In the placebo group dBP increased by 6 mmHg. The differences between the treatment 
groups regarding change in dBP after both first and second treatment periods were not 
significant (p=0.78 and p=0.18, respectively) (Table 16). 
QS2i shortened by 6 ms after the 2 mg daily dose and by 11 ms after the 6 mg daily dose 
compared with baseline. After the 4 mg daily dose QS2i shortened by 23 ms and after the 8 mg 
daily dose by 28 ms. In the placebo group QS2i shortened after 14 days by 8 and after 28 days 
by 2 ms compared with baseline. There was a statistically significant difference in the change in 
QS2i between treatment groups (p=0.02) at day 28, which is attributable to the difference 
between the high-dose group and the placebo group (p=0.005). After first treatment period no 
significant difference between the treatment groups was observed (p=0.11) (Table 16). 
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Table 16. Haemodynamic results after oral administration of levosimendan in study IV. 
 Low-dose (n=9) High-dose (n=8) Placebo (n=8) 
 Baseline 2mgx1 2mgx3 Baseline 2mgx2 2 mgx4 Baseline placebo placebo 
QS2i (ms) 533 ± 6* 527 ± 10 522 ± 4 538 ± 11 515 ± 13 510 ± 8 548 ± 7 540 ± 15 546 ± 16
HR (bpm) 71 ± 4 70 ± 4 81 ± 4 73 ± 5 81 ± 5 81 ± 6 66 ± 5 67 ± 7 71 ± 8 
sBP (mmHg) 122 ± 5 120 ± 5 121 ± 5 123 ± 8 128 ± 8 121 ± 6 117 ± 4 112 ± 5 112 ± 4 
dBP (mmHg) 78 ± 1 77 ± 2 72 ± 3 77 ± 4 78 ± 4 75 ± 4 71 ± 3 77 ± 4 77 ± 4 
5.1.2 Symptoms and signs 
Symptoms and signs were assessed in study I only. 
Dyspnoea and fatigue 
In study I, there were no differences between the five treatment groups in the degree to which 
dyspnoea had improved or worsened when recorded at the end of the study drug infusion, 
assessed either by the physician (p=0.41) or by the patient (p=0.46). There was a difference 
between the five treatment groups in the degree to which fatigue had improved or worsened 
when recorded at the end of study drug infusion, when assessed by the physician (p=0.04), but 
not when assessed by the patient (p=0.10). In the worst-rank symptom analysis, however, 
patients treated with levosimendan experienced worsening dyspnoea and fatigue less frequently 
than patients receiving placebo (Table 17). 






By patient    
Worsening dyspnoea (%) 11.0 16.7 0.06 
Worsening fatigue (%) 10.8 16.7 0.05 
By physician    
Worsening dyspnoea (%) 10.8 17.0 0.04 
Worsening fatigue (%) 10.6 17.0 0.05 
Other symptoms and signs 
In study I there were no differences among the five treatment groups regarding change of 
overall clinical status, chest pain, jugular venous distension or peripheral oedema. There were 
more patients in the levosimendan groups (10.3-14.7%) than in the placebo group (8.3%), who 
at the end of the study drug infusion did not have signs of left ventricular failure in the X-ray. 
However, the degree to which pulmonary congestion changed at the end of the study drug 
infusion was not significant between treatment groups (p=0.94). There were no differences 
between the treatments regarding change in urinary output during study infusion (p=0.51). 
New treatment for heart failure 
The prescribing of new medications for heart failure by the physician was utilized in study I as 
an additional surrogate measure of the efficacy of levosimendan. Analysis revealed that during 
the 6-hour infusion, patients assigned to placebo had a higher frequency than patients assigned 
to levosimendan (all groups combined) of the use of new medications for heart failure 
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(intravenous positive inotropic agents, vasodilators and diuretics), 13.7% vs. 7.2% (p=0.003) 
(Table 18). 
Table 18. Administration of new heart failure treatment in different dosing groups in study I 






Any new i.v. 
heart failure 
therapy 
 N % N % N % N % 
Placebo  4 3.9 8 7.8 4 3.9 14 13.7 
6 µg/kg +  
0.1 µg/kg/min 
2 1.9 4 3.9 4 3.9 8 7.8 
12 µg/kg + 
0.2 µg/kg/min 
1 1.0 6 6.0 3 3.0 7 7.0 
24 µg/kg +  
0.2 µg/kg/min 
1 1.0 5 5.1 1 1.0 7 7.1 
24 µg/kg + 
0.4 µg/kg/min 
0 0.0 5 5.1 3 3.0 7 7.1 
5.1.3 Morbidity and mortality 
Morbidity and mortality as endpoints were assessed in study I. 
In study I the combined risk of death and worsening heart failure was lower among patients 
treated with levosimendan than among patients receiving placebo both during the 6-hour 
infusion period (2.0% vs 5.9%, respectively; p=0.03), and during 24 hours after start of infusion 
(4.0% vs 8.8%, respectively; p=0.04). Three patients, one patient treated with levosimendan and 
two patients receiving placebo, experienced sudden death during the study (due to ventricular 
fibrillation), but were successfully resuscitated. When these patients are included in the analysis 
of morbidity and mortality, patients treated with levosimendan died, were resuscitated from 
sudden death or experienced worsening heart failure more frequently during the first 24 hours 
than patients assigned to placebo (4.2% vs 10.8%, p=0.01). 
The reduction of all-cause mortality among patients receiving levosimendan compared with 
placebo was seen already during the 6-hour study infusion. For the 14-day period after start of 
treatment all-cause mortality among levosimendan-treated patients was significantly lower than 
with placebo (11.7% vs 19.6%, respectively; 0.56 [95% CI 0.33-0.95]; p=0.03); this difference 
was seen also when the follow-up was extended to 180 days (22.6% vs 31.4%, respectively; 
0.67 [0.45-1.00]; p=0.05) (Figure 12). 
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Figure 12. Overall survival during 180 days after start of infusion in study I 
There was generally no relationship between the dose of levosimendan and mortality or 
combined risk of death and worsening heart failure. The only significant dose-relationship was 
seen regarding mortality during the 6-hour infusion (Table 19). 
Table 19. Incidence of death and worsening heart failure after administration of intravenous 






LS 6 µg/kg + 
0.1 µg/kg/min 
(n=103) 
LS 12 µg/kg + 
0.2 µg/kg/min 
(n=100) 
LS 24 µg/kg + 
0.2 µg/kg/min 
(n=99) 




Death or WHF 
at 6 hours (%) 
5.9 2.9 2.0 1.0 2.0 0.09 
Death or WHF  
at 24 hours (%) 
8.8 5.8 3.0 3.0 4.0 0.09 
Mortality  
at 6 hours (%) 
3.9 1.9 1.0 0.0 0.0 0.02 
Mortality  
at 24 hours (%) 
4.9 3.9 1.0 1.0 2.0 0.13 
Mortality  
at 72 hours (%) 
9.8 5.8 3.0 5.1 5.0 0.17 
Mortality  
at 14 days (%) 
19.6 12.6 10.0 13.1 11.0 0.11 
Mortality  
at 180 days (%) 
31.4 26.2 16.0 27.3 21.0 0.09 
*For dose-relation (CMH non-zero correlation test) 
Time (days)























5.1.4 Exercise test 
Levosimendan did not affect exercise capacity in two performed studies. As to the duration of 
the exercise test, in study III there was no significant difference between the treatments 
(p=0.09). In study IV, the 6-minute walk test did not show differences compared with the 
baseline between the groups after the first (p=0.81) or the second treatment period (p=0.33), 
even though improvement was highest in the high-dose levosimendan group. 
5.2 Pharmacokinetics 
In study II, the mean ± SEM levosimendan concentration in plasma at 30 minutes after start of 
the levosimendan 6-hour infusion was 12.8 ± 1.1 ng/ml and steady state concentrations of 
levosimendan were reached within 4 hours. At 4 hours the mean concentration was 42.6 ± 3.2 
ng/ml. The half-life was approximately 1 hour. The drug was eliminated fast, the mean AUClast 
was 230 ng·h/ml and it represented most of the total AUC extrapolated to infinity (236 
ng·h/ml). At 30 minutes after administration of the levosimendan 2 mg oral capsule, 
levosimendan concentrations were detected in most patients. The mean ± SEM plasma 
concentration was 16.1 ± 3.4 ng/ml. The mean concentration increased up to 1 h postdose, 
being 22.1 ± 3.3 ng/ml. The mean AUClast was 70.5 ng·h/ml and it represented most of the total 
AUC extrapolated to infinity (76.1 ng·h/ml). The bioavailability of oral levosimendan was 77 ± 
5%. 
In study III, the plasma concentrations of levosimendan and its metabolites were measured 
after each of the four 7- to 10-day treatment periods (Figure 9). The levosimendan 
concentration in plasma after 2 mg of levosimendan was 9.9 ± 4.5 ng/ml (mean ± SD) and it 
was 8.6 ± 2.7 ng/ml when levosimendan was administered concomitantly with 5 mg of 
felodipine. The mean plasma concentration of the metabolite OR-1855 was 3.0 ± 0.8 ng/ml 
when levosimendan was administered alone and 3.5 ± 0.8 ng/ml when levosimendan was 
administered concomitantly with felodipine. The plasma concentrations of the metabolite OR-
1896 were 3.3 ± 0.8 ng/ml and 2.9 ± 0.6 ng/ml with levosimendan alone and together with 
felodipine, respectively. 
In study IV, concentrations of both levosimendan and its metabolites were measured. 
Levosimendan pharmacokinetics was determined after the first 2 mg dose on the last day of a 
14-day treatment period. The mean Cmax for levosimendan was 38 ng/ml in patients receiving 
levosimendan 2 mg daily while it was about 25 ng/ml in those who received levosimendan 4-8 
mg daily (Table 20). This difference was related to an exceptionally high plasma concentration 
in one patient (95.9 ng/ml) in the low-dose group. However, if this patient were excluded from 
the analysis, the mean Cmax for this treatment period would be similar to that seen after the other 
periods. The mean tmax varied between 2.2-2.3 hours. No statistically significant difference was 
found in levosimendan pharmacokinetics between the medication periods and daily dose. 
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Table 20. Pharmacokinetic parameters of levosimendan on Day 14 after multiple dosing of 2 
mg oral levosimendan (one dosing interval) in study IV (mean ± SEM). 
 Low-dose (n=8) High-dose (n=8) 
 2mgx1 2mgx3 p-value* 2 mgx2 2mgx4 p-value* 
Cmax (ng/ml) 38 ± 10* 25 ± 7   0.31 25 ± 6 25 ± 5  0.98 
tmax (h) 2.2 ± 0.3 2.3 ± 0.2 0.99 2.3 ± 0.3 2.3 ± 0.3  0.98 
AUClast (ng·h/ml) 91 ± 24 57 ± 17  0.31 56 ± 13 56 ± 11  0.98 
* P-values show the relationships between the dose and Cmax, tmax or AUClast 
Cmax - peak concentration 
tmax – time of maximum concentration 
AUC - area under curve 
On day 14 the mean OR-1855 concentration in plasma was about 5 ng/ml in patients who 
received levosimendan 2 mg daily and about 15 ng/ml in the same patients when the dose was 
increased to 6 mg daily. The mean OR-1855 concentration in patients who received 4 mg daily 
was about 8 ng/ml and 17 ng/ml in the same patients when the dose was increased to 8 mg 
daily. The mean OR-1896 concentration on Day 14 was about 6 ng/ml after 2 mg levosimendan 
daily and about 17 ng/ml when the daily dose was increased to 6 mg. The mean OR-1896 
concentration was about 9 ng/ml after levosimendan 4 mg daily and 17 ng/ml in the same 
patients when they received 8 mg daily. The mean Cmax and AUC of both metabolites increased 
linearly within the patient groups (Table 21, Figure 13). 
Table 21. Pharmacokinetic parameters of levosimendan metabolites OR-1855 and OR-1896 
after multiple dosing of 2 mg oral levosimendan in study IV (mean ± SEM). 
 Low-dose (n=9) High-dose (n=7) p-value* 
 2mgx1 2mgx3 2mgx2 2mgx4  
OR-1855 Cmax (ng/ml) 5.2 ± 0.9* 15.3 ± 2.6 7.7 ± 1.6 17.1 ± 4.5  0.0006 
OR-1855 AUC0-8h (ng·h/ml) 40 ± 8 113 ± 20 59 ± 13 120 ± 32  0.002 
OR-1896 Cmax (ng/ml) 6.1 ± 1.4 16.9 ± 4.4 8.9 ±1.9 17.4 ± 2.3  0.0009 
OR-1896 AUC0-8h (ng·h/ml) 47 ± 11 126 ± 34 65 ± 13 128 ± 18  0.001  
* P-values show the relationship between the dose and Cmax or AUC0-8h. 
   Cmax - peak concentration 
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Figure 13. Plasma levels of levosimendan metabolites OR-1855 and OR-1896 in different dose 
groups after 14 days of treatment with oral levosimendan. 
5.3 Safety 
Hypotension and ischaemia in study I 
In study I, the primary variable was hypotension or ischaemia of clinical significance. Thus, it 
was primarily a safety study and a dedicated Safety Committee evaluated all cases of 
hypotension or ischaemia in a blinded fashion. 
Of the 504 randomized patients, 65 (12.9%) were deemed by the Safety Committee to have 
experienced ischaemic or hypotensive events that were "clinically significant". The distribution 
of these 65 patients among the five treatment groups is shown in Table 22. 
Table 22. Incidence of clinically significant hypotension and ischaemia after administration of 
intravenous levosimendan in study I 
 Placebo 
(n=102) 
LS 6 µg/kg +
0.1 µg/kg/min
(n=103) 
LS 12 µg/kg +
0.2 µg/kg/min
(n=100) 
LS 24 µg/kg + 
0.2 µg/kg/min 
(n=99) 
LS 24 µg/kg +
0.4 µg/kg/min
(n=100) 
Hypotension only 5 (4.9%) 7 (6.8%) 4 (4.0%) 5 (5.1%) 9 (9.0%) 
Ischaemia only 4 (3.9%) 0 (0.0%) 7 (7.0%) 5 (5.1%) 8 (8.0%) 
Hypotension and ischaemia 2 (2.0%) 4 (3.9%) 1 (1.0%) 2 (2.0%) 2 (2.0%) 
Hypotension and/or ischaemia 11 (10.8%) 11 (10.7%) 12 (12.0%) 12 (12.1%) 19 (19.0%) 
Overall, there were no significant differences among the five treatment groups in the proportion 
of patients that experienced the primary endpoint (p=0.32). When all four levosimendan groups 
were combined and compared with placebo, the proportions of patients who experienced 
clinically significant hypotension and/or ischaemia in the placebo and levosimendan groups 
were similar (10.8% vs 13.4%, respectively, p=0.46). There was, however, a weak relationship 
between the dose of levosimendan and the risk of hypotension and/or ischaemia (p=0.05), 
which was attributable to a higher frequency (19.0%) of ischaemia and hypotension among 
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patients who received the highest levosimendan infusion rate (24 µg/kg + 0.4 µg/kg/min), since 
the number of events in patients in other levosimendan groups were nearly identical to the 
number of events in patients receiving placebo. 
Adverse events 
In study I, adverse events were reported during the study infusion in 17.6% of the patients 
assigned to placebo and 23.4% of the patients assigned to levosimendan (p=0.23). The 
distribution of the most common adverse events (other than hypotension, ischaemia and 
worsening heart failure) is presented in Table 23. The highest frequency of arrhythmic disorders 
with levosimendan was seen with the infusion rate 0.4 µg/kg/min and the difference between 
treatment groups regarding sinus tachycardia was statistically significant. The incidence of 
myocardial ruptures was the highest among patients receiving placebo. 
Table 23. Adverse events with a frequency ≥ 1% during the 6-hour study drug infusion in  
study I 
Event Placebo LS 6 µg/kg + 
0.1 µg/kg/min 
LS 12 µg/kg + 
0.2 µg/kg/min 
LS 24 µg/kg + 
0.2 µg/kg/min 





1 (1.0%) 3 (2.9%) 1 (1.0%) 4 (4.0%) 6 (6.0%) 0.19 
Atrial 
fibrillation 
2 (2.0%) 1 (1.0%) 4 (4.0%) 3 (3.0%) 3 (3.0%) 0.65 
Other atrial 
arrhythmia 
1 (1.0%) 1 (1.0%) 1 (1.0%) 1 (1.0%) 2 (2.0%) 0.95 
Sinus 
tachycardia 
2 (2.0%) 0 (0.0%) 0 (0.0%) 3 (3.0%) 5 (5.0%) 0.03 
Headache 1 (1.0%) 2 (1.9%) 3 (3.0%) 1 (1.0%) 1 (1.0%) 0.79 
Agitation 2 (2.0%) 2 (1.9%) 1 (1.0%) 2 (2.0%) 0 (0.0%) 0.73 
Hypertension 1 (1.0%) 1 (1.0%) 3 (3.0%) 0 (0.0%) 0 (0.0%) 0.20 
Nausea 0 (0.0%) 1 (1.0%) 1 (1.0%) 2 (2.0%) 1 (1.0%) 0.61 
Myocardial 
rupture 
4 (3.9%) 1 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.03 
In study II, five patients out of 29 experienced adverse events during the whole course of the 
study. The most common adverse events were hypotension and ventricular extrasystoles. None 
of those adverse events led to premature discontinuation of the study drug infusion. One patient 
died suddenly four days after receiving a 2 mg single oral dose. One patient was hospitalised 
due to suspected increased blood digoxin level, but no confirmatory blood test was performed. 
In study III, levosimendan was well tolerated and the adverse events reported during the study 
were considered to be either mild or moderate. One patient experienced dizziness and one 
patient reported headache. No adverse events were reported during the concomitant 
administration of levosimendan and felodipine. One serious adverse event led to premature 
discontinuation of the study in one patient receiving felodipine and placebo. The patient was 
hospitalised with anginal pain, hypotension and ventricular extrasystoles. The event resolved 
and no myocardial injury was detected. 
In study IV, five patients out of 25 experienced adverse events during the study. All events 
were seen among patients receiving different doses of levosimendan. One patient experienced 
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atrial fibrillation when receiving the 6 mg daily dose of levosimendan. Another patient, 
receiving levosimendan 6 mg daily, discontinued the study due to sinus tachycardia and angina 
pectoris. However, no rise of cardiac enzymes was seen and no myocardial injury was detected. 
Safety laboratory parameters 
In study I serum CK-MB was measured at baseline and at the end of study infusion. There 
were no significant differences between the five treatment groups in the change in CK-MB at 6 
hours (p=0.09). In studies II-IV there were only minor changes in the laboratory parameters. 
The only notable changes were small decreases in serum potassium and blood haemoglobin, 
hematocrit and leukocytes with levosimendan. 
Holter monitoring 
24-hour ECG recording (Holter) was carried out in studies II-IV. In study II, during and after 
the 6-hour infusion some increase in the number of ventricular extrasystoles per hour in 
comparison with screening was observed (74 vs 104), except after intake of the 2 mg oral 
capsule (74 vs 64). Number of runs + VTs per 24 hours decreased compared with baseline both 
after infusion and after intake of the 2 mg capsule (6 vs 2 and 3, respectively). In study III the 
incidence of clinically significant arrhythmias was small and no differences regarding the 
incidence of arrhythmias were observed between treatments, neither was there any significant 
difference between treatments regarding the number or total duration of episodes of ST-
segment changes (p=0.52 and p=0.48, respectively). In study IV, there were no differences 
between treatment groups regarding arrhythmic disorders after either treatment period. 
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6. Discussion 
6.1 Study population 
The study populations in the four studies differed as to severity and acuteness of IHD. Study I 
enrolled patients with acute recent ischaemia and severe heart failure, whereas study III 
included patients with stable IHD and studies II and IV patients with stable heart failure of 
ischaemic origin. This is explained by the studies having different aims. While study I primarily 
evaluated the safety of the short-term infusion of levosimendan in the acute setting, studies II-
IV evaluated mainly the pharmacodynamics and pharmacokinetics of the drug in the chronic 
setting. 
Intravenous inotropic drugs are indicated in patients with peripheral hypoperfusion with or 
without pulmonary congestion or with oedema refractory to diuretics and vasodilators. As this 
condition often occurs due to acute ischaemia, especially after AMI, the highly symptomatic 
patient population in study I is relevant also in terms of clinical practice. In studies II and IV the 
patient population consisted of ischaemic NYHA class III-IV heart failure patients. This patient 
population has been considered to gain the most benefit from treatment with positive inotropic 
drug as seen from the DIG trial, where the greatest effect was seen among class III-IV heart 
failure patients (371). The patients included in study III represent the largest group of IHD 
patients, for whom anti-ischaemic treatment is most commonly targeted. Therefore, one can 
conclude that the patient population included in these trials was clinically relevant for 
evaluation of the treatment effects of levosimendan. 
The population of the studies consisted mainly of male patients, except the study I population, 
where almost half of the patients were women. This is noteworthy, since the patient population 
in most clinical studies consists predominantly of male patients. The patients in that study had 
also the worst prognosis, the severest clinical condition and highest incidence of different 
concomitant diseases such as hypertension and diabetes. 
6.2 Background therapy 
In all studies the study treatment was administered in addition to the patients’ normal 
medication for IHD and heart failure. The use of different treatments reflects the severity of 
disease, but also the data that were available at time the studies were conducted. There are some 
important differences between the studies regarding concomitant treatment. For example, the 
frequency of use of ACE inhibitors and beta-blockers was quite low in study I (47% and 39%, 
respectively), despite the fact that they have been recommended for these patients by cardiology 
societies. One possible explanation for the low frequency of administration of beta-blockers is 
concomitant severe left ventricular failure in patients with AMI, which may have caused some 
reluctance to administer these drugs since no conclusive evidence about the usefulness of beta-
blockers in patients with pulmonary congestion or oedema was available at the time the study 
was performed. It is also possible that the low frequency of use of ACE inhibitors was due to 
the relatively low blood pressure at baseline in certain patients. The use of thrombolytics in 
study I was lower than the use reported in epidemiological trials with patients from Western 
Europe (469, 470). It is interesting, however, that in study I these concomitant treatments were 
administered in rather similar frequency as in the USA (471, 472). 
In studies II and IV ACE inhibitors were administered to almost all patients, but beta-blockers 
only to one third. Nitrates, ASA and calcium antagonists were administered in relatively similar 
frequency in all studies, except in study III, in which the administration of calcium antagonists 
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other than felodipine was excluded. Anticoagulants (heparin) were administered solely as 
treatment of AMI, in study I. 
6.3 Haemodynamic effects 
Haemodynamics was assessed in all studies using non-invasive methods. In addition to 
assessments used in everyday clinical practice – blood pressure and heart rate - also systolic 
time intervals were used for assessment of inotropic effect. 
Blood pressure decreased after intravenous administration of levosimendan in similar fashion in 
studies I and II with the maintenance infusion rate of 0.2 µg/kg/min. Despite different baseline 
conditions the blood pressure response was rather similar in these two studies. The decrease in 
sBP at 6 hours was relatively similar (5 mmHg in study I and 7 mmHg in study II) and so was 
the incidence of hypotension (4.5% in study I and 6.8% in study II). The lower incidence of 
hypotension in study I may be related to the somewhat higher baseline values than in study II; 
on the other hand, the patients in study I were more unstable. It is noteworthy that the 
administration of the loading dose in study I did not cause an increase in the incidence of 
hypotension compared to study II, indicating that the administration of a 10-minute loading 
dose does not involve a safety risk, even in acute patients. 
After administration of oral levosimendan the overall changes in blood pressure were small. 
The changes compared with placebo or baseline varied from a decrease of 3 mmHg to an 
increase of 5 mmHg. Study II provided the possibility to make a rather direct comparison with 
respect to change in blood pressure between the oral and intravenous formulations of 
levosimendan. Comparison of the decrease in sBP after intravenous and oral dosing revealed 
about two times greater decrease after intravenous administration, which was probably caused 
by the two times higher levosimendan plasma levels. Considering that the daily doses of oral 
levosimendan varied from 2 to 8 mg, it can be concluded that oral levosimendan administered 
in single doses up to 2 mg and daily doses up to 8 mg does not produce a clinically relevant 
change in blood pressure. 
Levosimendan exhibited a chronotropic effect in all studies. After 6-hour infusion the increase 
in HR was approximately 2-4 bpm with a 0.2 µg/kg/min dose, but after the 0.4 µg/kg/min dose 
the increase in HR was 11 bpm, which may increase the risk of arrhythmic events. After 
administration of oral levosimendan an increase in HR was seen only after multiple dosing, but 
not after administration of a single dose, suggesting that the chronotropic effect of 
levosimendan at these doses is most probably connected with the accumulation of the active 
metabolite OR-1896. A similar observation has been made also in a previous study with 24-
hour intravenous infusion (442). It seems that plasma concentrations of levosimendan higher 
than those achieved after a single oral dose of 2 mg are needed to reveal the chronotropic effect 
of levosimendan. Since the heart rate is the most significant easily measurable change in 
haemodynamics after administration of oral levosimendan, it can aid in establishing safe dose 
regimens. 
Systolic time intervals, mainly heart rate-corrected electromechanical systole (QS2i), which has 
been considered fairly specific and load-independent variable, were used for assessment of the 
inotropic effects of levosimendan and its metabolites (473). The inotropic effect observed after 
6-hour infusion of 0.2 µg/kg/min levosimendan was rather moderate. The most commonly 
studied daily dose of oral levosimendan was 2 mg, administered altogether to 60 patients. The 
shortening of QS2i in these studies varied from 6-10 ms, which is similar to the change seen 
after 6-hour infusion. The concentration-effect loop curves for QS2i (inotropy) and blood 
pressure (vasodilation) showed counter-clockwise hysteresis, meaning that the time of the peak 
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response lagged behind the time of the peak drug concentration. This can be explained by the 
time the drug requires to distribute to its cardiac site of action (equilibration delay). These loop 
curves also revealed that the vasodilatory effect appears before inotropy, which is important 
from the clinical perspective. 
The inotropic response was rather similar when levosimendan was administered concomitantly 
with felodipine as it was with levosimendan alone, indicating that the administration of a 
calcium antagonist does not abolish the calcium sensitizing effect. 
While study II concentrated on the inotropic effect of just levosimendan, the inotropic effects of 
its metabolites also were assessed in study IV. The different daily doses in study IV produced 
linearly increasing metabolite levels, but the effects of the different metabolite levels on the 
index of inotropy were not so clear-cut. For example, the result for the 2 mg dose was similar 
after it was administered as a single dose and after longer administration, where the 
contribution of the active metabolite could be expected. It seems that the metabolite 
concentration of levosimendan after the 2 mg daily dose did not reach a level that would have 
produced significant additional inotropic effect. In favor of such an explanation speaks also the 
lack of carry-over effects as regards inotropy in study III. 
When daily doses higher than 2 mg were administered, the total inotropic effect increased, but 
no dose response was observed, as shown by the effect being more pronounced with the 4 mg 
than with the 6 mg daily dose and by QS2i not shortening significantly further in the second 14-
day administration period from that seen after the first 14-day administration. The evident lack 
of dose response may have occurred due to the small number of patients in the treatment group, 
but it is also possible that some form of tolerance to the inotropic action of the metabolite is 
developed. The latter consideration needs further clarification, as the metabolite levels were 
significantly higher after the second than after the first period and should have resulted in 
higher inotropic responses. 
6.4 Symptoms 
The assessment of symptomatic improvement is always challenging and easily open to 
criticism. Indeed there is very little well-controlled data in acute ischaemic patients in that 
respect. One reason is probably the absence of validated and well-recognised methods. Also the 
severity of clinical condition complicates the assessment, since, although the studied drug itself 
may have a real effect in relieving symptoms, quite a large proportion of severely ill patients 
receiving placebo may also improve as they will almost always receive other 
haemodynamically active treatments together with the study treatment (474). Therefore, the 
proper evaluation of symptoms should take into account several aspects of the clinical course of 
the patients, such as newly administered concomitant treatments, important clinical events and 
deaths. 
In study I the “worst-rank” assessment method was applied for evaluation of dyspnoea and 
fatigue and it showed that patients in the placebo group worsened more often than patients in 
the levosimendan group. One important contribution to this result, in addition to mortality, was 
also a significant reduction in the need for additional heart failure therapy, as would be 
expected for an effective therapy for the failing heart. It is important that this result was 
observed in a situation in which haemodynamics was not invasively monitored, i.e. 
investigators had no knowledge of the cardiac output or filling pressures at the time of the 
assessments. Indeed, in the recent VMAC study with nesiritide, an improvement in dyspnoea 
was observed only in patients who were invasively monitored, but not in those who were not, 
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indicating that physician’s knowledge of haemodynamics might affect the symptom evaluation 
of the patient (475). 
6.5 Morbidity and mortality 
An endpoint combining morbidity and mortality - “death and worsening heart failure” – was 
used in study I. This endpoint combines the most important clinical events that may occur in 
this patient population. The difference in favor of levosimendan was seen early, already during 
the 6-hour infusion period and also 24 hours after randomization. The positive effect of 
levosimendan in this endpoint is remarkable, since no other intravenous inotropic drug has ever 
achieved a similar result in any clinical study. 
The most striking result of the study was the lower all-cause mortality among patients receiving 
levosimendan. The difference between levosimendan and placebo was seen already at 6 hours 
and the benefit continued up to 180 days after infusion. From Kaplan-Meier curves it is evident 
that the risk reduction attributable to levosimendan was actually achieved during the first 14 
days of follow-up. The Kaplan-Meier curves are parallel after 14 days indicating no further 
additional survival benefit after that time. 
There are many possible mechanisms how levosimendan could improve the prognosis of acute 
ischaemic patients. First, the cardioprotective effect may be related to the potassium-channel 
opening mechanism, for example via coronarodilation and possibly via the ischaemic 
preconditioning mechanism. K+ATP openers are agents that induce or enhance ischaemic 
preconditioning and may thereby decrease myocardial injury and cell death (96, 423). 
Levosimendan has also been shown to improve the function of the stunned myocardium in 
acute myocardial ischaemia (458). A recent study has shown that levosimendan protects the 
myocardium from reactive oxygen species-mediated apoptosis, which can also explain the 
observed beneficial effects of levosimendan (476). This is probably related to the calcium 
sensitising effect of the drug as a decreased sensitivity of the myofibrils to calcium appears to 
be responsible for the contractile depression of the myocardium. An intriguing observation was 
the decrease in the incidence of myocardial ruptures among levosimendan-treated patients. This 
result can be explained by a recent result of a clinical study, where levosimendan decreased 
myocardial wall stress, which can contribute to the reduction of frequency of myocardial 
rupture among patients with AMI (423). A similar result has been observed in a previous beta-
blocker trial (166). 
The mortality results should also be considered in the context of pharmacokinetics. One 
previous study evaluating the effects of a 24-hour infusion of levosimendan, at the rate 0.2 
µg/kg/min, showed that levosimendan metabolites were first detected in plasma approximately 
at the end of infusion and were seen in plasma during the next 10-14 days (442). After the 6-
hour infusion in study I the administered amount of levosimendan would be four times lower 
than after 24-hour infusion, and therefore one could predict that also the metabolite 
concentration would be four times lower, but the accumulation-elimination curve would be 
similar to that seen after 24-hour infusion. This indicates that the positive long-term effect of 
levosimendan regarding mortality is probably due to the positive effect of its metabolite(s), 
whereas the short-term benefit may be related to the cardioprotective effect of the parent drug. 
The active metabolite OR-1896 has been shown to be a calcium sensitizer, but no information 
about its effects on potassium channels is available. This indicates that a calcium sensitisation 
effect per se may be involved in the improvement of prognosis. The effect of intravenous 
levosimendan should therefore be viewed as a dual effect: the short-term effect of 
levosimendan and the long-term effect of the metabolite(s). 
 74 
When evaluating the mortality results in study I, one should take into account that the study was 
not prospectively designed and powered to show a difference in mortality. Two currently 
ongoing large randomized prospective trials in patients experiencing severe decompensated 
heart failure should conclusively show whether levosimendan has a positive effect on the short-
and long-term outcomes of these patients (454, 455). 
6.6 Safety 
Levosimendan was rather well-tolerated in all studies. A higher frequency of hypotension, 
ischaemia and also arrhythmic events were seen in comparison with placebo only with the 
highest, 0.4 µg/kg/min infusion rate. 
In studies with oral levosimendan the frequency of adverse events was small and did not differ 
from that seen in comparative treatment groups. It seems, however, that daily doses higher than 
4 mg may not be well tolerated during long-term administration, mainly due to the increase in 
heart rate. 
No significant changes were seen in most laboratory values. Oral levosimendan decreased 
haemoglobin, hematocrit and leukocytes after approximately 1-month treatment by 7-9%. The 
exact mechanism of these changes is unknown. Decrease in serum potassium was similar to that 
seen in earlier studies. 
24-hour ECG recording (Holter) was carried out in studies II-IV. Some beneficial anti-
ischaemic effects were seen in study III, since the Holter recordings during the administration 
of levosimendan showed reduction of both duration and number of ST-depression and -
elevation episodes compared with placebo and the effect was similar to that seen with 
felodipine. In study II there were no changes in frequency of malignant arrhythmic events 
compared with baseline after either the infusion or the single oral administration. No 
differences between treatment groups were observed in study IV. However, taking into account 
the heart rate increase after daily doses of 6 and 8 mg it is still possible that with these doses 
also the frequency arrhythmic events would have increased, had the study treatment groups 
included more patients. Indeed, the increased frequency of ventricular arrhythmias has been 
considered one of the contributing factors to increased mortality with inotropic agents (477). 
Therefore, one can conclude that daily doses of oral levosimendan beyond 4 mg are probably 
too high for clinical use. 
6.7 Feasibility of levosimendan in long-term treatment 
The feasibility of the long-term administration of levosimendan revolves around its complex 
pharmacokinetics and the long-lasting haemodynamic effects resulting from its metabolites. 
The key issue in terms of the clinical use of the drug seems to be the reaching of such 
metabolite plasma levels that would be clinically effective, but also safe in the long term. Study 
I showed indirectly that the plasma level of levosimendan achieved after a 6-hour infusion 
would be safe in long term as all doses decreased the incidence of worsening heart failure and 
mortality compared with placebo. However, due to increased incidence of hypotension and 
ischaemia during infusion (short-term safety) with the infusion rate 0.4 µg/kg/min, this rate is 
not suitable for therapeutic use in patients with acute ischaemia. The results showed indirectly 
also the favorable safety profile of the metabolite levels after all doses of levosimendan. 
As intravenous levosimendan was administered only once and for only 6 hours, the possible 
effects of repeated and longer administration of levosimendan are not known. Of special 
interest would be the situation in which a new levosimendan infusion would be administered 
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within 14 days of the previous infusion, i.e. on top of the existing pharmacodynamic effects of 
the metabolites. Knowledge about the effects of intermittent administration would have a great 
importance, since acute patients may often need repeated administration of the drug due to 
severely compromised haemodynamics. Such a study including a re-administration component 
in its design will hopefully provide information about this issue (455). 
The clinical effects of also oral levosimendan are closely related to the pharmacokinetics of the 
drug, and specifically to the effects of the metabolites. Taking into account the half-life of the 
metabolites (70-80 h), it can be considered that steady-state plasma concentrations of 
metabolites will be achieved after approximately 14 days of treatment. Since single doses of 1 
or 2 mg have been shown to produce significant haemodynamic and inotropic effects, the 
appropriate daily dose for long-term administration is closely related to the metabolite level 
which is achieved when these doses are administered long-term. To find the dose which is 
effective and safe during long-term administration is of crucial importance, since the long half-
life of the metabolites makes their effects (also possible adverse ones) long-lasting. It seems 
that administration of oral levosimendan at the dose of 2 mg was safe also on top of existing 
metabolite levels and did not cause unexpected adverse effects. At the same time it was 
revealed that metabolite levels above 9 ng/ml have a significant chronotropic effect. Taking this 
into account, one can consider that the administration of approximately 2 mg once or twice 
daily as a single dose of levosimendan may be optimal for both efficacy and safety. In any case, 
the effects of levosimendan after long-term oral administration need further clarification. 
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7. Limitations of the studies 
The 14-day mortality follow-up in study I was rather short with respect to safety. Although 
mortality was studied, adverse events were not comprehensively followed during the follow-up 
period. Also data about concomitant medication administered during the follow-up would have 
added value to the observed mortality result. In addition, the sample size of the trial was too 
small to provide conclusive evidence about the morbidity/mortality effects of intravenous 
levosimendan in the studied population. 
Study II was an open label study without a control group. Although a placebo group was not 
necessary for the evaluation of PK-PD interrelationships of levosimendan, it would have had 
value for the evaluation of safety. The PK-PD interrelationships of levosimendan, but not its 
metabolites’ were assessed. The latter would have substantially increased the value of the 
current results. 
Study III was carried out using a cross-over design. In spite of the fact that a cross-over design 
is rather often used in interaction trials, the decision to use it in a trial with a drug having long-
lasting metabolites was not the optimal one. Although no carry-over effects were seen, the 
design could have been improved by adding wash-out periods after each treatment period. A 
14-day period (instead of 7-10 days) would have been more optimal, since the steady-state of 
metabolites would have been reached by day 14. 
In study IV the two-week treatment periods were unfortunately too short to see any 
improvements regarding exercise capacity. However, the study provided important information 
regarding PK-PD relationships of different doses, which is needed for dose selection in long-
term administration. 
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8. Summary and conclusions 
The purpose of the present study was to investigate the effects of levosimendan in patients with 
ischaemic heart disease with or without concomitant heart failure. Intravenous levosimendan 
was studied in patients with acute or chronic ischemia, complicated by severe heart failure. In 
addition the study provided information about the effects of long-term oral administration of 
levosimendan in chronic ischaemia and ischaemic heart failure settings. Altogether 557 patients 
were studied in this thesis, 504 of them experiencing acute and 53 chronic ischaemia. 
The main conclusions of the study: 
1) Levosimendan, administered as 6-hour intravenous infusion in doses of 0.1 or 0.2 
µg/kg/min, did not increase clinically significant ischaemia or hypotension in patients 
with AMI complicated by severe left ventricular failure. Levosimendan decreased also the 
incidence of worsening heart failure and reduced both short- and long-term mortality. The 
infusion rate 0.4 µg/kg/min was associated with an increased risk of clinically significant 
hypotension and ischaemia and is therefore not suitable for use in acute ischaemic 
patients. 
2) The inotropic and vasodilatory effects of oral levosimendan resembled those seen after 
intravenous administration. These pharmacodynamic effects appeared almost 
simultaneously, although the vasodilatory effect was seen earlier after intravenous than 
after oral administration. Chronotropic effects of intravenous levosimendan in doses of 
0.1 or 0.2 µg/kg/min were small, whereas the dose 0.4 µg/kg/min had significant 
chronotropic effects and increased also the frequency of arrhythmic events. 
3) Oral levosimendan administered in doses of 2 or 4 mg daily was well tolerated and had 
moderate inotropic and chronotropic effects in patients with ischaemia or ischaemic heart 
failure. The results indicate that the inotropic effect of the calcium sensitizer is not 
attenuated by ischaemia or treatment with a calcium antagonist. The doses beyond 4 mg 
daily possessed significant chronotropic effects and are therefore not suitable for clinical 
use. The vasodilatory effects of oral levosimendan after long-term administration were 
small. Oral levosimendan did not increase exercise capacity in ischaemic patients whether 
they had concomitant heart failure or not. The overall effect of the drug on ischaemia is 
neutral. 
4) Pharmacokinetics of oral levosimendan is independent of the dosing interval. The 
formation of levosimendan metabolites increases linearly with the daily dose. The 
chronotropic effects after long-term administration of daily doses beyond 4 mg are related 
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